var title_f16_47_17136="Headache diary PI";
var content_f16_47_17136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 578px\">",
"   <div class=\"ttl\">",
"    Headache diary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 558px; height: 625px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bristol-Myers Squibb Company. Copyright 2001 Bristol-Myers Squibb Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17136=[""].join("\n");
var outline_f16_47_17136=null;
var title_f16_47_17137="Invasive diarrhea";
var content_f16_47_17137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Invasive diarrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The appearance of frank blood in the stool constitutes invasive diarrhea.",
"    <br>",
"     (A) Melenic stool with abundant mucous.",
"     <br>",
"      (B) Watery stool with blood and mucous.",
"      <br>",
"       (C) Bloody, mucoid stool.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17137=[""].join("\n");
var outline_f16_47_17137=null;
var title_f16_47_17138="Patient information: Multiple sclerosis in children (The Basics)";
var content_f16_47_17138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83436\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/15/14580\">",
"         Multiple sclerosis in children",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/43/3763\">",
"         Patient information: Meningitis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/31/40447\">",
"         Patient information: Multiple sclerosis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/48/1796\">",
"         Patient information: Meningitis in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Multiple sclerosis in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/multiple-sclerosis-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H98769235\">",
"      <span class=\"h1\">",
"       What is multiple sclerosis in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Multiple sclerosis in children is a disease that can cause vision problems, movement problems, and other symptoms. It happens when the body&rsquo;s infection-fighting system attacks and damages nerve cells (",
"      <a class=\"graphic graphic_figure graphicRef83278 \" href=\"UTD.htm?14/15/14580\">",
"       figure 1",
"      </a>",
"      ). The infection-fighting system is called the &ldquo;immune system.&rdquo; When it attacks the body&rsquo;s own cells, this is called an &ldquo;autoimmune response.&rdquo;",
"     </p>",
"     <p>",
"      Many people call multiple sclerosis &ldquo;MS.&rdquo;",
"     </p>",
"     <p>",
"      There are several types of MS. Most children have a type called &ldquo;relapsing-remitting MS.&rdquo; In this type, the MS symptoms come and go. When a person has more symptoms than usual, this is called an attack. An attack can last several days or weeks. It usually goes away slowly. Between attacks, a person might feel normal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769250\">",
"      <span class=\"h1\">",
"       What are the symptoms of MS in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Vision problems, eye pain, and odd eye movements",
"       </li>",
"       <li>",
"        Feeling dizzy or off-balance - This can cause the child to fall.",
"       </li>",
"       <li>",
"        Weakness and stiffness in the face or an arm or leg &ndash; This usually affects just 1 side of the body.",
"       </li>",
"       <li>",
"        Problems controlling the bowels or bladder",
"       </li>",
"       <li>",
"        Feeling very tired, depressed, or less active than usual",
"       </li>",
"       <li>",
"        Getting sick with a fever, headache, vomiting, and stiff neck &ndash; These are less common symptoms of MS in children, but they happen sometimes.",
"       </li>",
"       <li>",
"        Seizures &ndash; Seizures are waves of abnormal electrical activity in the brain. During a seizure, a child might have sudden jerking or twitching movements.",
"       </li>",
"       <li>",
"        Confusion, memory problems, trouble thinking clearly, or changes in mood",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Every child with MS does not get all the symptoms. Some children might have just 1 or a few symptoms. The symptoms might come and go at different times.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769265\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your child should see a doctor or nurse right away if he or she has any of the symptoms above and you do not know the cause. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769280\">",
"      <span class=\"h1\">",
"       Is there a test for MS in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes and no.",
"      <strong>",
"      </strong>",
"      Doctors can order tests, but the tests might not show MS right away. With MS, symptoms and test results can change with time. Sometimes, doctors have to check a child again, or do more tests, before they are sure about MS.",
"     </p>",
"     <p>",
"      If the doctor thinks your child might have MS, he or she can order the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        MRI &ndash; This imaging test uses powerful magnets to create pictures of the inside of the body. To look for MS, doctors usually do an MRI of the brain and sometimes of the spinal cord. The MRI can show if the nerves are damaged.",
"       </li>",
"       <li>",
"        Lumbar puncture (also known as a &ldquo;spinal tap&rdquo;) &ndash; During this procedure, a doctor puts a thin needle in the lower back and removes a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. He or she will do lab tests on the spinal fluid. Changes in this fluid can be a sign of MS.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The doctor will also do an exam and ask about your child&rsquo;s symptoms. Tell the doctor or nurse if someone in your family has MS.",
"     </p>",
"     <p>",
"      Many other conditions can cause symptoms similar to MS in children. The doctor can order other tests to look for these conditions.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769297\">",
"      <span class=\"h1\">",
"       How is MS in children treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors cannot cure MS in children or adults. But they can give medicines to treat the attacks. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Steroid medicines &ndash; These can make attacks shorter. These medicines are different than the steroids athletes take to build muscle.",
"       </li>",
"       <li>",
"        &ldquo;Disease-modifying therapy&rdquo; &ndash; These medicines lower the chance of having an MS attack. These medicines do not cure MS, and doctors do not know if they slow it down. Most of these medicines come as injections (shots). Many children learn to give themselves the shots.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors can also treat symptoms of MS. Many people with MS, including children, get very tired. They might also feel depressed, have problems thinking, or have muscle spasms. If your child has any symptoms, tell the doctor or nurse, even if you do not think they have anything to do with MS. The doctor or nurse can offer your child special treatments for those symptoms. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769312\">",
"      <span class=\"h1\">",
"       What will my child&rsquo;s life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you just learned your child has MS, try to stay positive. In most children, MS is a very slow disease. &nbsp;",
"     </p>",
"     <p>",
"      The medicines used to treat MS are often very good at keeping attacks from happening. Some people with relapsing-remitting MS go many months or years without having attacks. Even so, doctors cannot tell how fast MS will get worse for any one person. Some children do very well. Other children lose the ability to do some things over years or decades.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98769327\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=see_link\">",
"       Patient information: Multiple sclerosis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/43/3763?source=see_link\">",
"       Patient information: Meningitis in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1796?source=see_link\">",
"       Patient information: Meningitis in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/47/17138?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83436 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17138=[""].join("\n");
var outline_f16_47_17138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769235\">",
"      What is multiple sclerosis in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769250\">",
"      What are the symptoms of MS in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769265\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769280\">",
"      Is there a test for MS in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769297\">",
"      How is MS in children treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769312\">",
"      What will my child&rsquo;s life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98769327\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83436\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/15/14580\">",
"      Multiple sclerosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1796?source=related_link\">",
"      Patient information: Meningitis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/43/3763?source=related_link\">",
"      Patient information: Meningitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=related_link\">",
"      Patient information: Multiple sclerosis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_47_17139="Azelastine (ophthalmic): Drug information";
var content_f16_47_17139=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azelastine (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/17/38164?source=see_link\">",
"    see \"Azelastine (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/19/31026?source=see_link\">",
"    see \"Azelastine (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7977087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Optivar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7977092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7977128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Seasonal allergic conjunctivitis:",
"     </b>",
"     Ophthalmic: Instill 1 drop into affected eye(s) twice daily.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7977127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/19/31026?source=see_link\">",
"      see \"Azelastine (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Seasonal allergic conjunctivitis:",
"     </b>",
"     Ophthalmic: Children &ge;3 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7977129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15794420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15794421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7977140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 0.05% (6 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Optivar&reg;: 0.05% (6 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7977090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7977094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of itching of the eye associated with seasonal allergic conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7977085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Optivar&reg; may be confused with Optiray&reg;, Optive&trade;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Optivar [U.S.] may be confused with Opthavir brand name for acyclovir [Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7977103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Transient burning/stinging (30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Bitter taste (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis, eye pain, blurred vision (temporary)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, dyspnea, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7977099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to azelastine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7977100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Solution contains benzalkonium chloride; remove lens prior to administration and wait at least 10 minutes before reinserting. Do not use contact lenses if eyes are red.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9770046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7977095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7977096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have shown toxic effects to the fetus at maternally toxic doses.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7977098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7977142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Azelastine HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (6 mL): $104.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Optivar Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (6 mL): $174.19",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alergot (VE);",
"     </li>",
"     <li>",
"      Allergodil (AT, BE, CH, CZ, DE, DK, EE, FR, IT, NL, PT, RU);",
"     </li>",
"     <li>",
"      Az Ofteno (CN, CR, DO, GT, HN, NI, PA, SV, VE);",
"     </li>",
"     <li>",
"      Azel (CO);",
"     </li>",
"     <li>",
"      Brixia (AR, CN, PY, UY);",
"     </li>",
"     <li>",
"      Eyezep (AU, KP);",
"     </li>",
"     <li>",
"      Lastin (FI, SE);",
"     </li>",
"     <li>",
"      Oculast (IN);",
"     </li>",
"     <li>",
"      Opthazel (PE);",
"     </li>",
"     <li>",
"      Optilast (IL);",
"     </li>",
"     <li>",
"      Xanaes (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7977115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells and inhibits the release of histamine and other mediators involved in the allergic response",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7977117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: 3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Plasma concentrations following ocular administration are low for azelastine (0.02-0.25 ng/mL) and n-desmethylazelastine (0.25-0.87 ng/mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8677 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-2F8DE301F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17139=[""].join("\n");
var outline_f16_47_17139=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977087\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977092\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977128\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977127\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977129\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15794420\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15794421\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977140\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977090\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977094\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977085\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977103\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977099\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977100\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298803\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770046\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977095\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977096\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977098\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977142\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961954\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977115\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977117\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8677\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8677|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8022?source=related_link\">",
"      Azelastine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/54/12132?source=related_link\">",
"      Azelastine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/20/5445?source=related_link\">",
"      Azelastine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/17/38164?source=related_link\">",
"      Azelastine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/19/31026?source=related_link\">",
"      Azelastine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_47_17140="Sucralfate: Patient drug information";
var content_f16_47_17140=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sucralfate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     see \"Sucralfate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/4/8261?source=see_link\">",
"     see \"Sucralfate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carafate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sucralfate;",
"     </li>",
"     <li>",
"      Dom-Sucralfate;",
"     </li>",
"     <li>",
"      Novo-Sucralate;",
"     </li>",
"     <li>",
"      Nu-Sucralate;",
"     </li>",
"     <li>",
"      PMS-Sucralate;",
"     </li>",
"     <li>",
"      Sucralfate-1;",
"     </li>",
"     <li>",
"      Sulcrate&reg;;",
"     </li>",
"     <li>",
"      Sulcrate&reg; Suspension Plus;",
"     </li>",
"     <li>",
"      Teva-Sucralfate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12784501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat oral and esophageal (swallowing tube) ulcers.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702962",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sucralfate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696825",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids 30 minutes before or after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11055 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F93BED5DA7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17140=[""].join("\n");
var outline_f16_47_17140=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223520\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223521\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12784501\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019797\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019796\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019801\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019802\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019804\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019799\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019800\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019805\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019806\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=related_link\">",
"      Sucralfate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/4/8261?source=related_link\">",
"      Sucralfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_47_17141="Trandolapril and verapamil: Patient drug information";
var content_f16_47_17141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Trandolapril and verapamil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/29/37336?source=see_link\">",
"     see \"Trandolapril and verapamil: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tarka&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tarka&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to trandolapril, verapamil, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the kidneys' arteries or other kidney disease, hyperaldosteronism, low blood pressure, Lown-Ganoang-Levine syndrome, very weak heart, slow heartbeat without a working pacemaker, or Wolff-Parkinson-White syndrome.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696480",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11112 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17141=[""].join("\n");
var outline_f16_47_17141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229930\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229931\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022097\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022099\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022098\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022103\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022104\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022106\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022101\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022102\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022107\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022108\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/29/37336?source=related_link\">",
"      Trandolapril and verapamil: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_47_17142="Antioxidants and atherosclerosis";
var content_f16_47_17142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Schematic representation of antioxidant actions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 654px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incorporation of antioxidants into low density lipoprotein (LDL) protects against oxidation of LDL particles. Additionally, the incorporation of antioxidants into vascular cells may inhibit the vascular response to oxidized LDL.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17142=[""].join("\n");
var outline_f16_47_17142=null;
var title_f16_47_17143="Stereotactic body radiation therapy for primary and metastatic lung tumors";
var content_f16_47_17143=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stereotactic body radiation therapy for primary and metastatic lung tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/47/17143/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17143/contributors\">",
"     Josh H Heinzerling, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17143/contributors\">",
"     Robert D Timmerman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/47/17143/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17143/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17143/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/47/17143/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17143/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/47/17143/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic body radiation therapy (SBRT) is a technique that utilizes precisely targeted radiation to a tumor while minimizing radiation to adjacent normal tissue. This targeting allows treatment of small- or moderate-sized tumors in either a single or limited number of dose fractions.",
"   </p>",
"   <p>",
"    Stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) initially was used successfully for intracranial, orbital, and base of skull tumors, as well as benign conditions that can use the skull as a reference system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The success of SRS for intracranial indications led to the development of techniques to extend this approach to extracranial targets. Stereotactic radiation therapy for extracranial sites has required significant technical advances including tumor imaging to guide radiation administration, patient immobilization, and conformal radiation delivery techniques.",
"   </p>",
"   <p>",
"    SBRT has been defined by the American College of Radiology (ACR) and American Society of Therapeutic Radiology and Oncology (ASTRO) as the use of very large doses per fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/1\">",
"     1",
"    </a>",
"    ]. SBRT has unique radiobiological characteristics, which can cause dramatic tumor response, leading to the associated term \"ablative\" radiotherapy.",
"   </p>",
"   <p>",
"    The rationale for SBRT in treating both primary non-small cell lung cancer (NSCLC) and metastatic lung tumors, specific techniques, and early results with this technique will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUES FOR LUNG TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximity of lung tumors to critical thoracic structures requires that the high doses of oligofractionated radiation therapy used in SBRT be delivered accurately and precisely to minimize normal tissue exposure to radiation. SBRT thus requires reliable and reproducible patient immobilization, daily imaging for accurate repositioning from simulation to treatment, use of multiple treatment fields, and a method of accounting for tumor and organ motion during treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patient positioning and immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consistent, reproducible, and comfortable patient immobilization is essential for ensuring treatment accuracy.",
"   </p>",
"   <p>",
"    There are several commercially available systems designed for stereotactic patient positioning and immobilization, including body frames, vacuum cushions, and thermal plastic restraints. These devices typically feature a stereotactic fiducial system that is rigidly attached and registered to the target. Other, so called \"frameless\" systems rely on methods to effectively relocate a reference position within the patient. As an example, implanted fiducial seeds within the tumor can be accurately relocated on a daily basis using imaging techniques. Newer technologies under development include electromagnetic transponders that can be tracked throughout treatment to ensure accurate positioning during the entire treatment course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Image guided treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sophisticated image guidance, typically with computed tomography (CT), is incorporated into the treatment unit and allows validation of patient positioning prior to each treatment. Image guided radiation therapy minimizes the uncertainty associated with external reference points and allows accurate tumor localization in near real time. Because lung tumors are very distinct on CT scan, pretreatment reference volumes can be linked to the image and appropriate adjustments can be reliably made on the day of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tumor motion control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung tumors often move relative to other thoracic structures during the respiratory cycle. This motion can vary significantly depending upon the location of the tumor and patient characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several methods exist to reduce or compensate for tumor motion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal compression places a pressure device on the abdomen to reduce motion related to the diaphragm.",
"     </li>",
"     <li>",
"      Deep inspiration and breath holding attempts to arrest the tumor in a reproducible position within the respiratory cycle.",
"     </li>",
"     <li>",
"      Respiratory gating combines these approaches to trigger delivery of radiation during a specific segment of the respiratory cycle.",
"     </li>",
"     <li>",
"      Tumor tracking systems actually move the radiation beam to follow the motion of the tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the method used, careful assurance of accuracy, reproducibility, as well as implementation of motion data into treatment planning, is essential for precise treatment delivery with SBRT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;SBRT utilizes advanced treatment planning approaches to minimize radiation exposure outside the planned tumor volume. This is accomplished by using multiple beams (typically 10 to 12) or large angle arc rotations. Use of non-opposing beams is encouraged to avoid overlap of dose at points of entrance and exit. In most circumstances, non-coplanar beams are preferred to further spread out the entrance and exit dose within normal tissues.",
"   </p>",
"   <p>",
"    Target volumes are determined using mechanisms to predict and quantify tumor motion such as four-dimensional CT and fluoroscopy. When tumor is hard to differentiate from normal tissue, advanced imaging techniques such as",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    or MRI can be combined with CT to accurately determine tumor volume. As an example, in lung tumors adjacent to the chest wall or associated with lung atelectasis or consolidation,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    can help delineate targets more precisely.",
"   </p>",
"   <p>",
"    Reducing high doses of incidental radiation outside the intended treatment volume is critical to preventing normal tissue toxicity with the high dose fractions used in SBRT. Protocols commonly define criteria related to the conformality of target dose and compactness of intermediate dose. In addition, normal tissue dose constraints are being developed and modified based on existing data from patients treated with SBRT to help predict toxicity based on dose-volume relationships.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRIMARY NSCLC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection remains the standard therapy for patients with stage I non-small cell lung cancer (NSCLC), with five-year survival rates of approximately 60 to 70 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of stage I and stage II non-small cell lung cancer\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medically inoperable patients have often been treated with standard fractionated radiotherapy. Doses of 45 to 66 Gy in fractions of 1.8 to 2 Gy over six weeks have resulted in five-year survival rates of approximately 10 to 30 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of stage I and stage II non-small cell lung cancer\", section on 'Definitive RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SBRT has been studied in phase I and II studies for inoperable patients, and ongoing phase III studies are comparing SBRT with surgery for patients with localized tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Observational studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two prospective phase II studies illustrate the results with SBRT in treating patients with NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter study from the Radiation Therapy Oncology Group (RTOG 0236), 59 patients with biopsy-proven peripheral T1T2N0M0 tumors were treated with 54 Gy in three fractions. Patients with tumors &lt;2 cm from the \"proximal bronchial tree\" were excluded (",
"      <a class=\"graphic graphic_figure graphicRef66569 \" href=\"UTD.htm?33/25/34199\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/11\">",
"       11",
"      </a>",
"      ]. At a median follow-up of 34 months, the three-year primary tumor control rate in the 55 evaluable patients was 98 percent, and the three-year control rate for the primary tumor plus lobe was 91 percent. The three-year disease-free and overall survival rates were 48 and 56 percent, respectively. There were two grade four adverse events and no treatment-related fatalities.",
"     </li>",
"     <li>",
"      In a prospective phase II Nordic study, 57 patients with T1 or T2 N0M0 NSCLC were treated with SBRT (15 Gy times three) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/12\">",
"       12",
"      </a>",
"      ]. The three-year progression-free, cancer-specific, and overall survival rates were 52, 88, and 60 percent, respectively.",
"     </li>",
"     <li>",
"      The Nordic Cooperative group studied SBRT in medically inoperable patients with stage I non&ndash;small-cell lung cancer (NSCLC) in a prospective phase II study [12]. Fifty-seven patients with T1NOMO (70 percent) or T2N0M0 (30 percent) were treated with SBRT to a total dose of 45 Gy in 3 fractions, prescribed to the 67 percent isodose to the planning target volume. With a median follow-up of 35 months, the overall- and cancer-specific survival at three years was 60 and 88 percent, respectively. The Kaplan-Meier estimated local control at three years was 92 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of both of these smaller prospective studies are confirmed by a large single institution experience that included 676 patients treated between 2003 and 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/13\">",
"     13",
"    </a>",
"    ]. In that study, median overall survival was 41 months (95% CI 35-47 months), local control was 89 percent at five years, and the most likely pattern of failure was distant relapse (66 percent of the 124 total relapses observed in the study).",
"   </p>",
"   <p>",
"    SBRT may have a particular role in patients with severe chronic obstructive pulmonary disease (COPD). In a single-institution cohort study of 176 such patients, the actuarial three-year local control rate was 89 percent, and the one- and three-year overall survival rates were 79 and 47 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/14\">",
"     14",
"    </a>",
"    ]. In this patient population, treatment avoided the risk of operative mortality.",
"   </p>",
"   <p>",
"    In addition, SBRT may have an important role in patients who otherwise would choose no active therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In an observational study from the Netherlands, patterns of care and outcome were analyzed in 875 patients (age 75 years or older) treated between 1999 and 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/16\">",
"     16",
"    </a>",
"    ]. This period was divided into the period before SBRT was introduced (1999 to 2001), partial availability (2002 to 2004), and full accessibility (2005 to 2007). Over the three periods, there was a progressive increase in the use of radiotherapy (26, 32, and 42 percent, respectively), with 23 and 55 percent of RT using SBRT in the second and third periods. There was a concomitant decrease in the fraction of patients opting for no active treatment (38, 32, and 26 percent, respectively). There was a statistically significant increase in survival associated with the use of SBRT, whereas outcomes remained constant over the three periods with surgery or observation.",
"   </p>",
"   <p>",
"    The optimal dose and schedule for SBRT of early stage lung tumors remains uncertain. Dose fractionation schemes differ between reported series (",
"    <a class=\"graphic graphic_table graphicRef74458 \" href=\"UTD.htm?5/20/5453\">",
"     table 1",
"    </a>",
"    ). The optimal dose fractionation schedule may vary with tumor stage and location, and no randomized studies have been performed thus far comparing different fractionation schemes.",
"   </p>",
"   <p>",
"    Two ongoing studies being conducted by the RTOG may provide additional information about the optimal dose and schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      study (RTOG 0813, NCT00750269) is evaluating escalating doses delivered in five fractions for centrally located tumors. The goal of this trial is to determine whether a modified schedule may minimize toxicity for centrally located tumors. The starting dose is 50 Gy in five fractions (10 Gy per fraction) with escalation to 12 Gy per fraction for tumors located within the proximal bronchial tree (",
"      <a class=\"graphic graphic_figure graphicRef66569 \" href=\"UTD.htm?33/25/34199\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A phase II study (RTOG 0915, NCT00960999) is randomly assigning medically inoperable patients with peripheral stage I tumors to either 34 Gy in one fraction or 48 Gy in four fractions. The least toxic of these two regimens will be compared to the 60 Gy in three fraction regimen used in RTOG 0236.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     SBRT versus surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operable patients are divided into two categories based on therapeutic options: 1. Average risk (likely able to tolerate a lobectomy), and 2. High risk (likely able to tolerate a sublobar resection but not a lobectomy). Those unable to tolerate any of these surgical options are called medically inoperable. The results from observational studies suggest that the results with SBRT for stage I disease are similar to those with surgery in similar risk groups [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An international phase III trial organized by the MD Anderson Cancer Center (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00840749?term=NCT00840749&amp;rank=1\">",
"     NCT00840749",
"    </a>",
"    ) is randomly assigning 420 high or average risk patients with T1 or T2 (&lt;4 cm) NSCLC to surgery or SBRT (for four fractions for central lesions [each 15 Gy] or for three fractions for peripheral lesions [each 20 Gy]). The primary objective is a comparison of overall survival at three years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second cooperative group phase III trial being sponsored by the American College of Surgeons, 420 high risk patients with a clinical stage I NSCLC and a primary tumor &le;4 cm are being randomly assigned to sublobar resection (with or without internal radiation therapy, iodine I-125) or to SBRT (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01336894?term=NCT01336894&amp;rank=1\">",
"     NCT01336894",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Another phase III trial (ROSEL,",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00687986?term=NCT00687986&amp;rank=1\">",
"     NCT00687986",
"    </a>",
"    ) comparing SBRT with surgery was terminated because of poor patient recruitment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LUNG METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs are one of the most common sites of spread of disease for patients with a wide variety of primary tumors. Although this usually is a manifestation of widespread disease, carefully selected patients benefit from surgical resection of one or a limited number of lung metastases when this is the sole site of recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SBRT appears to be an effective and well tolerated local therapy for patients with limited metastatic disease within the lung. Local control rates in patients with lung metastases have ranged from 67 to 92 percent using various dose fractionation schemes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/19-24\">",
"     19-24",
"    </a>",
"    ]. These results suggest that SBRT provides equivalent local control to surgical resection; thus SBRT may be an alternative to surgery in patients with oligometastatic disease.",
"   </p>",
"   <p>",
"    The potential role of SBRT in patients with lung metastases is illustrated by two large series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      study of 38 patients, each with one to three enlarging pulmonary metastases, the SBRT dose was escalated from 48 to 60 Gy given divided into three fractions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/19\">",
"       19",
"      </a>",
"      ]. None of the 12 patients in the phase I portion of the study experienced a dose limiting toxicity. In an analysis of the assessable 50 lesions, actuarial local control rates at one and two years were 100 percent and 96 percent, respectively.",
"     </li>",
"     <li>",
"      Similar results were observed in a single-institution analysis of patients with oligometastatic disease (five or fewer lesions), in which SBRT was used to treat 103 lung metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/20\">",
"       20",
"      </a>",
"      ]. Local control was achieved in 90 (87 percent). A subsequent further analysis from the same center observed that SBRT was used to retreat nine lesions that had relapsed following initial treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high doses per fraction used during SBRT, there is an increased risk of normal tissue toxicity compared to conventionally fractionated radiation therapy unless care is taken to minimize radiation exposure to normal structures. The numbers of patients and length of follow-up are limited in the studies described above. However, prospective assessment of dosimetric endpoints such as dose volume information has been used to modify SBRT dose constraints in normal tissues and SBRT for thoracic lesions appears to have a reasonable safety profile.",
"   </p>",
"   <p>",
"    The phase II study conducted at Indiana University found that central and perihilar structures within the lung are very sensitive to the high doses of radiation delivered during SBRT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/25\">",
"     25",
"    </a>",
"    ]. Low-grade toxicities included fatigue, musculoskeletal pain, and radiation pneumonitis. Fourteen patients had severe toxicity, including decline in pulmonary function tests, pleural effusions, and pneumonias. There were six deaths that may have been treatment-related, the majority of which were from pneumonia. Four of the six deaths were in patients with central tumors, and these patients had an 11-fold increased risk of having a severe toxicity compared to patients with peripheral lesions. An RTOG clinical study (RTOG 0813, NCT00750269) is evaluating different SBRT regimens to treat tumors located within the zone of the proximal bronchial tree [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The RTOG has observed reasonable rates of toxicity for treatment of medically inoperable patients when the SBRT dose is divided into three fractions for peripheral tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/11\">",
"     11",
"    </a>",
"    ]. Grade 3 to 4 toxicity was seen in 15 patients (28 percent) treated on RTOG 0236, and no treatment related deaths were seen. Other studies have also observed that SBRT was well tolerated, and that changes in pulmonary function tests were minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When SBRT is used to treat primary lung cancers in apical sites, there may be an increased risk of injury to the brachial plexus. In a series of 36 patients with apical lesions treated with SBRT to a median dose of 57 Gy in three fractions, seven patients developed grade 2, 3, or 4 brachial plexopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/27\">",
"     27",
"    </a>",
"    ]. These authors felt that the tolerance of the major trunks of the brachial plexus was around 26 Gy for a three fraction regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=see_link&amp;anchor=H4#H4\">",
"     \"Complications of peripheral nerve irradiation\", section on 'Late-delayed brachial plexopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For lesions near the lung periphery, chest wall toxicity may be manifested by rib fractures or pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The incidence of chest wall toxicity was illustrated by a series of 347 treated lesions, which included 203 on the chest wall. Both chest wall pain and rib fractures were more frequent when chest wall lesions were irradiated compared with nonchest wall lesions (16 versus 3 percent and 8 versus 1 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When SBRT is used to treat patients with lung metastases, toxicity is typically less severe than that for those with primary lung cancer. These patients tend to present with better overall lung function and are more likely to have peripherally located tumors. In the multicenter dose-escalation study, no grade 4 to 5 toxicity was seen, and there were no treatment-related deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17143/abstract/19\">",
"     19",
"    </a>",
"    ]. Although multiple patients had more than one lesion treated with SBRT, only three had grade 3 toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic body radiation therapy (SBRT) is a radiation therapy technique that utilizes precisely targeted radiation to a tumor while minimizing radiation to adjacent normal tissue. This targeting allows treatment of small- or moderate-sized tumors in either a single or limited number of dose fractions. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Techniques for lung tumors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Application of SBRT techniques in patients with small primary non-small cell lung cancers (NSCLCs) or lung metastases has given results similar to surgical resection, although long-term follow-up data are not available. There are no results from randomized clinical trials comparing SBRT to surgery or other ablative techniques such as radiofrequency ablation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25255?source=see_link\">",
"     \"Radiofrequency ablation of lung tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Primary non-small cell lung cancer",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with adequate pulmonary function and without serious medical comorbidity, we recommend surgical resection as the initial treatment for patients with stage I or II NSCLC rather than medical management or conventional radiation therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest surgical resection rather stereotactic body radiation therapy (SBRT) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). There are no trials that compare SBRT with radiofrequency ablation (RFA). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of stage I and stage II non-small cell lung cancer\", section on 'Surgery'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Primary NSCLC'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25255?source=see_link\">",
"       \"Radiofrequency ablation of lung tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with primary tumors less than 5 cm and impaired pulmonary function or medical comorbidity that precludes surgical resection, we suggest ablative therapy with SBRT rather than definitive radiation therapy, if appropriate technical expertise is available (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). To date, there are no studies that compare SBRT versus RFA in these patients. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Primary NSCLC'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25255?source=see_link\">",
"       \"Radiofrequency ablation of lung tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with larger primary tumors and impaired pulmonary function or medical comorbidity that precludes surgical resection, we suggest definitive radiation therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of stage I and stage II non-small cell lung cancer\", section on 'Definitive RT'",
"      </a>",
"      .) To date, there are no studies that compare SBRT versus RFA in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lung metastases",
"    </span>",
"   </p>",
"   <p>",
"    For patients with a limited number of small lung metastases who meet the criteria for resection, we suggest surgery rather than ablative therapy with SBRT (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). SBRT may be preferred in patients with significant medical comorbidity who are thus not candidates for surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link&amp;anchor=H5#H5\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\", section on 'Criteria for resection'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Lung metastases'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25255?source=see_link\">",
"     \"Radiofrequency ablation of lung tumors\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/1\">",
"      Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010; 76:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/2\">",
"      Heinzerling JH, Anderson JF, Papiez L, et al. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys 2008; 70:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/3\">",
"      Liu HH, Balter P, Tutt T, et al. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys 2007; 68:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/4\">",
"      Lax I, Blomgren H, N&auml;slund I, Svanstr&ouml;m R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 1994; 33:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/5\">",
"      Negoro Y, Nagata Y, Aoki T, et al. The effectiveness of an immobilization device in conformal radiotherapy for lung tumor: reduction of respiratory tumor movement and evaluation of the daily setup accuracy. Int J Radiat Oncol Biol Phys 2001; 50:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/6\">",
"      Wulf J, H&auml;dinger U, Oppitz U, et al. Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame. Radiother Oncol 2000; 57:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/7\">",
"      Kimura T, Hirokawa Y, Murakami Y, et al. Reproducibility of organ position using voluntary breath-hold method with spirometer for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/8\">",
"      Wang LT, Solberg TD, Medin PM, Boone R. Infrared patient positioning for stereotactic radiosurgery of extracranial tumors. Comput Biol Med 2001; 31:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/9\">",
"      Sharp GC, Jiang SB, Shimizu S, Shirato H. Prediction of respiratory tumour motion for real-time image-guided radiotherapy. Phys Med Biol 2004; 49:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/10\">",
"      Schweikard A, Shiomi H, Adler J. Respiration tracking in radiosurgery. Med Phys 2004; 31:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/11\">",
"      Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/12\">",
"      Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27:3290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/13\">",
"      Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012; 13:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/14\">",
"      Palma D, Lagerwaard F, Rodrigues G, et al. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys 2012; 82:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/15\">",
"      Haasbeek CJ, Lagerwaard FJ, Antonisse ME, et al. Stage I nonsmall cell lung cancer in patients aged &gt; or =75 years: outcomes after stereotactic radiotherapy. Cancer 2010; 116:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/16\">",
"      Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010; 28:5153.",
"     </a>",
"    </li>",
"    <li>",
"     NIH clinical trials database: file://www.clinicaltrials.gov.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/18\">",
"      De Ruysscher D, van Elmpt W, Lambin P. Radiotherapy with curative intent for lung cancer: a continuing success story. Radiother Oncol 2011; 101:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/19\">",
"      Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009; 27:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/20\">",
"      Milano MT, Katz AW, Schell MC, et al. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/21\">",
"      Milano MT, Philip A, Okunieff P. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys 2009; 73:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/22\">",
"      Hof H, Hoess A, Oetzel D, et al. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol 2007; 183:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/23\">",
"      Hara R, Itami J, Kondo T, et al. Stereotactic single high dose irradiation of lung tumors under respiratory gating. Radiother Oncol 2002; 63:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/24\">",
"      Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006; 45:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/25\">",
"      Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24:4833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/26\">",
"      Stephans KL, Djemil T, Reddy CA, et al. Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 2009; 4:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/27\">",
"      Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009; 93:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/28\">",
"      Voroney JP, Hope A, Dahele MR, et al. Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. J Thorac Oncol 2009; 4:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/29\">",
"      Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving &gt;30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17143/abstract/30\">",
"      Andolino DL, Forquer JA, Henderson MA, et al. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Int J Radiat Oncol Biol Phys 2011; 80:692.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4617 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-518C2F532B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17143=[""].join("\n");
var outline_f16_47_17143=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUES FOR LUNG TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patient positioning and immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Image guided treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tumor motion control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment planning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRIMARY NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Observational studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SBRT versus surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LUNG METASTASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Primary non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lung metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4617\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4617|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/25/34199\" title=\"figure 1\">",
"      Bronchial tree anat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4617|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/20/5453\" title=\"table 1\">",
"      SBRT LC stage1 lung CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=related_link\">",
"      Management of stage I and stage II non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25255?source=related_link\">",
"      Radiofrequency ablation of lung tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_47_17144="Treatment of cervical radiculopathy";
var content_f16_47_17144=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of cervical radiculopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/47/17144/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17144/contributors\">",
"     Jenice Robinson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17144/contributors\">",
"     Milind J Kothari, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/47/17144/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17144/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/47/17144/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17144/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/47/17144/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimum treatment of compressive cervical radiculopathy is the subject of continued debate, and initial management may vary significantly among practitioners. There is sparse evidence that any treatment improves upon the natural history of the condition. Part of the problem is that cervical radiculopathy is a clinical, and to some extent subjective, diagnosis with no \"gold standard\" test to establish or exclude the disease. Depending upon the diagnostic criteria used, clinical studies evaluating the treatment of cervical radiculopathy have tended to select one subset of patients more than another. As an example, studies that require the presence of a surgically demonstrated lesion to establish the diagnosis of cervical radiculopathy are likely to exclude patients with mild or improving symptoms.",
"   </p>",
"   <p>",
"    The treatment of cervical radiculopathy will be reviewed here. The clinical features and diagnosis of cervical radiculopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis varies in part upon whether the cervical radiculopathy is compressive or noncompressive. The majority of radiculopathies arise from nerve root compression; the two predominant mechanisms are cervical spondylosis and disc herniation. Noncompressive radiculopathy includes diabetes and infectious, granulomatous, and infiltrating neoplastic disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Compressive radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, some, if not most, patients with compressive cervical radiculopathy improve without specific treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Evidence that improvement is not treatment specific comes from a population-based study of 561 patients with cervical radiculopathy from Rochester, Minnesota [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/2\">",
"     2",
"    </a>",
"    ]. This was not a natural history study, since most patients received some treatment and 26 percent had surgery for cervical radiculopathy. Nevertheless, at last follow-up, 90 percent of patients were asymptomatic or only mildly incapacitated.",
"   </p>",
"   <p>",
"    Given the apparent overall good prognosis for recovery, conservative therapies are preferred in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Triage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients without evidence of specific weakness who have clear radicular pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms of only paresthesia or numbness should be managed conservatively. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Conservative therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is important to examine the patient carefully for any evidence of superimposed spinal cord dysfunction (ie, myelopathy), since cervical spondylosis may cause spinal cord compression as well as nerve root compression. In addition, all patients with objective weakness should have early cervical spine imaging and electrodiagnostic studies.",
"   </p>",
"   <p>",
"    Myelopathy results in specific abnormalities on neurologic examination. Motor signs of myelopathy below the level of spinal cord involvement include upper motor neuron type weakness, increased reflexes and tone, and Babinski signs. Lower motor neuron type weakness may occur at the level of spinal cord compression. Sensory signs include decreased pinprick sensation below the level of spinal cord involvement and loss of position or vibration sensation in the lower extremities. These examination findings may be subtle if spinal cord compression is mild.",
"   </p>",
"   <p>",
"    Evidence of myelopathy, as determined by the presence of myelopathic signs on examination, combined with neuroimaging evidence of spinal cord compression, is an indication for surgery. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Indications for surgery'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of myelopathy, conservative initial management is usually indicated for patients with stable motor weakness, as it is for patients without motor deficits on examination. All patients with motor weakness should be closely followed for evidence of progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Noncompressive radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of noncompressive cervical radiculopathy or polyradiculopathy include infectious processes (especially herpes zoster and Lyme disease), nerve root infarction, root avulsion, infiltration by tumor, infiltration by granulomatous tissue, and demyelination (",
"    <a class=\"graphic graphic_table graphicRef63137 \" href=\"UTD.htm?16/34/16939\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\", section on 'Noncompressive causes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis of cervical radiculopathy in these settings is influenced by the natural history and response to therapy of the underlying condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NONSURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main components of nonsurgical therapy: conservative therapy and epidural glucocorticoid injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Conservative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative therapy of cervical radiculopathy typically consists of the following modalities, alone or in some combination [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral analgesics",
"     </li>",
"     <li>",
"      A short course of oral corticosteroids",
"     </li>",
"     <li>",
"      Avoidance of provocative activities",
"     </li>",
"     <li>",
"      Cervical traction",
"     </li>",
"     <li>",
"      Short-term neck immobilization with the use of a hard or soft cervical collar",
"     </li>",
"     <li>",
"      Use of a cervical pillow",
"     </li>",
"     <li>",
"      Physical therapy with exercise and gradual mobilization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few randomized trials have evaluated the effectiveness of these treatments. One trial of 205 adults with acute cervical radiculopathy diagnosed by a neurologist found that treatment with either physical therapy and home exercises for six weeks or a cervical collar and rest for three to six weeks was superior to no treatment (control) for reduction in neck and arm pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/5\">",
"     5",
"    </a>",
"    ]. Observational studies suggest that conservative therapy for cervical radiculopathy is associated with complete resolution of pain and neurologic deficits in 40 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. However, it remains uncertain whether conservative therapy improves upon the natural history of cervical radiculopathy.",
"   </p>",
"   <p>",
"    Despite uncertainty regarding effectiveness, we suggest conservative therapy as initial treatment for most patients with cervical radiculopathy who have clear radicular pain and symptoms of paresthesia or numbness. In addition, we suggest conservative therapy as initial treatment for patients with cervical radiculopathy who have nonprogressive neurologic deficits, including dermatomal sensory loss, myotomal weakness, and sensory changes, as long as myelopathy is not suspected.",
"   </p>",
"   <p>",
"    There is no consensus regarding the sequence or time course of conservative modalities. We generally start treatment with oral analgesics and avoidance of provocative activities, accompanied by a short course of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    if pain is severe. For oral analgesia, we typically use nonsteroidal antiinflammatory drugs (NSAIDs) as first-line therapy. We avoid the use of narcotic agents.",
"   </p>",
"   <p>",
"    A muscle relaxant such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    may be added if muscle spasm or muscle tightness is prominent. Cyclobenzaprine is generally started at a modest dose of 5 mg two or three times a day to reduce the side effect of drowsiness. The dose can be increased to 10 mg three times a day after one week if spasm is not relieved and side effects are not prominent.",
"   </p>",
"   <p>",
"    Shoulder abduction, which can be used as a diagnostic sign, can also be useful for temporary symptom relief [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\", section on 'Shoulder abduction relief test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the pain is tolerable, we initiate physical therapy with exercise and gradual mobilization. In our opinion, prolonged inactivity may delay recovery and is not advisable.",
"   </p>",
"   <p>",
"    The patient should be seen and reexamined in six to eight weeks if there is no improvement with these conservative measures. In this setting, neuroimaging studies of the cervical spine and electrodiagnostic studies should be performed if they were not done initially. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Refractory or progressive symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A short course of high-dose oral glucocorticoid therapy may be used as initial treatment for patients with severe cervical radicular pain. The only evidence supporting the effectiveness of oral glucocorticoids for cervical radiculopathy is anecdotal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/4\">",
"     4",
"    </a>",
"    ]. In our clinical experience, for example, this treatment is associated with pain relief in many patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    60 to 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for five days, followed by a taper off the medication over the ensuing 5 to 14 days, is a typical regimen. We suggest not using prophylaxis against gastrointestinal bleeding in patients taking prednisone alone. In contrast, patients taking prednisone in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other NSAIDs may require prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H10#H10\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Prevention strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Exercise therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical therapy, range-of-motion exercises, strengthening exercises, and aerobic exercises are frequently employed as conservative measures for cervical radiculopathy. These treatments are unproven, and the few controlled trials showed conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/5,11\">",
"     5,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients report benefit with exercise therapy, but this could reflect the natural history of the disease or a placebo response. Because of possible benefit and no proven harm, we suggest exercise therapy as part of the initial treatment of symptomatic cervical radiculopathy in the absence of myelopathy. Exercise therapy is contraindicated in the presence of myelopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cervical traction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical traction is the application of a distracting force to the neck, which can in theory separate the cervical segments, expand the intervertebral joint spaces, and relieve compression of the nerve roots [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, controlled studies of cervical traction delivered in the course of a physical therapy program for a variety of causes of neck and arm pain have not demonstrated benefit over sham traction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/12\">",
"     12",
"    </a>",
"    ] or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no meta-analyses or systematic reviews of traction as treatment for the specific diagnosis of cervical radiculopathy. A 1995 systematic review of traction for patients with neck or back pain was unable to determine if traction was effective, mainly because the included studies had methodologic flaws, including insufficient power [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/14\">",
"     14",
"    </a>",
"    ]. Similarly, a 2006 systematic review of traction for patients with mechanical neck disorders reported that the evidence of benefit for traction was inconclusive, due to low methodologic quality of the trials [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006 systematic review suggested that intermittent as opposed to continuous traction may be beneficial, although the evidence came from low-quality trials [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, an early observational study found that intermittent cervical traction was associated with symptom relief in some patients with cervical radiculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traction should not be used unless neuroimaging has been performed, and should be discontinued if symptoms worsen with the application of distracting force. Traction is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in the presence of spinal cord compression or large disc protrusion.",
"   </p>",
"   <p>",
"    We generally do not prescribe cervical traction as initial therapy for patients with cervical radiculopathy. Nevertheless, cervical traction is a reasonably safe alternative for patients with persistent or refractory pain who do not want epidural glucocorticoid injections or surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Refractory or progressive symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with cervical radiculopathy have symptoms that are refractory to conservative treatments, and a smaller number develop progressive symptoms.",
"   </p>",
"   <p>",
"    Clinical reevaluation should be performed with careful assessment for motor weakness and myelopathic findings in patients who have not improved after six to eight weeks of conservative treatment or in those who have progressive symptoms. Neuroimaging and electrodiagnostic studies are indicated, particularly if not done initially, and repeat electrodiagnostic studies may be needed if an initial study was unrevealing.",
"   </p>",
"   <p>",
"    Reevaluation, neuroimaging, and electrodiagnostic studies are important to ensure that the initial diagnosis of radiculopathy is correct, and to assess for evidence of progressive neurologic deficit that could be an indication for surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14\">",
"     'Indications for surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are no clinical trials that clearly establish whether more aggressive interventions, such as epidural steroid injections or surgery, are beneficial for patients who are refractory to conservative therapy or beneficial for those who have progressive symptoms or signs. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Epidural glucocorticoid injections'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nevertheless, many experts consider unremitting radicular pain despite six to eight weeks of conservative treatment, progressive motor weakness, or signs and symptoms of myelopathy (in the context of imaging studies showing a surgically remediable anatomic spinal cord compression) as indications for surgery. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Indications for surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Symptoms of cervical radiculopathy recur in up to one-third of patients after initial improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/2\">",
"     2",
"    </a>",
"    ]. Conservative management should be reemployed when symptoms recur, unless a significant motor deficit or myelopathy is present. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Conservative therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Epidural glucocorticoid injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent cervical radicular pain, with or without radiculopathy, may benefit from epidural glucocorticoid injections, but the data are weak and inconsistent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small prospective [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/17,18\">",
"       17,18",
"      </a>",
"      ] and retrospective [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/19,20\">",
"       19,20",
"      </a>",
"      ] observational studies suggest that transforaminal or interlaminar epidural glucocorticoid injections provide substantial relief lasting six months or longer in 40 to 60 percent of patients. However, these observational studies cannot distinguish between improvement due to treatment or to the natural history of cervical radiculopathy.",
"     </li>",
"     <li>",
"      No benefit of epidural glucocorticoid injection was found in a small trial that randomly assigned patients with cervical radiculopathy to treatment with either local anesthesia and epidural glucocorticoid injection (n = 20) or local anesthesia and saline injection (n = 20) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/21\">",
"       21",
"      </a>",
"      ]. At three weeks, there was no difference between the two groups for the outcome of a reduction of arm pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurologic symptoms (30 percent each).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike lumbar injections, fluoroscopic guidance is mandatory for cervical epidural injections. The needle should remain in contact with the posterior wall of the intervertebral foramen; this position avoids contact with the nerve root, spinal nerve, and associated vessels (",
"    <a class=\"graphic graphic_figure graphicRef65832 \" href=\"UTD.htm?0/50/807\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Test injections of small amounts of nonionic contrast can confirm entry of the needle into the epidural space and demonstrate whether the injectate spreads onto the injured nerve root(s). Test contrast injections can also reveal inadvertent intraarterial injection. The use of computed tomography (CT) fluoroscopy for guidance may provide improved anatomic detail compared with standard fluoroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious complications of cervical epidural glucocorticoid injections are rare, but the precise incidence of such complications is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/25\">",
"     25",
"    </a>",
"    ]. There have been well-documented reports of death or severe neurologic sequelae from hemorrhage or infarction involving the brain, brainstem, cerebellum, or spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/26\">",
"     26",
"    </a>",
"    ]. The exact cause of neurologic injury is uncertain in most reported cases, but possible mechanisms include embolism of glucocorticoid particles due to inadvertent injection into a vertebral or a radicular artery, arterial dissection, needle-induced vasospasm, and unintentional dural puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/22,25-28\">",
"     22,25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one autopsy study, death due to a stroke with massive cerebral edema occurred following dissection of and subsequent thrombus formation in the vertebral artery during a C7 epidural injection [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, death due to extensive brainstem and thalamic infarction occurred following epidural injection despite the use of fluoroscopic guidance; at autopsy, there was a small area of hemorrhage within the adventitia of the left vertebral artery but no dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A physician survey evaluating complications of cervical transforaminal epidural glucocorticoid injections found that all neurologic complications occurred after injections of particulate glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      ), whereas none occurred after injections of the nonparticulate glucocorticoid",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with confirmed cervical radiculopathy who have severe or disabling pain despite a reasonable course (six to eight weeks) of conservative therapy, and who do not have a progressively worsening neurologic deficit, we suggest the use of epidural steroid injections rather than surgery, provided that the injections are performed by experienced centers and interventionalists under fluoroscopic guidance using test contrast injection to identify accidental vessel injection. Use of a nonparticulate glucocorticoid such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    may reduce the risk of ischemic complications.",
"   </p>",
"   <p>",
"    The role of epidural glucocorticoid injections in patients with low back pain is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=see_link\">",
"     \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of surgery for the treatment of cervical radiculopathy has not been clearly established, and data from controlled trials are sparse.",
"   </p>",
"   <p>",
"    A 2010 systematic review identified only a single small randomized trial of surgery versus conservative management for the treatment of cervical radiculopathy that met criteria for inclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/31\">",
"     31",
"    </a>",
"    ]. In this trial, which evaluated 81 patients with clinical and radiological signs of nerve root compression lasting more than three months, patients were randomly assigned to treatment with either surgery (anterior cervical discectomy), physiotherapy, or immobilization with a hard cervical collar [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/32\">",
"     32",
"    </a>",
"    ]. Those with spinal cord compression, whiplash, and other serious associated diseases were excluded.",
"   </p>",
"   <p>",
"    The following results were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At four months, the surgically treated patients showed greater improvement in pain, muscle strength, and sensory loss than the nonsurgically treated patients",
"     </li>",
"     <li>",
"      At one year, there was no significant difference in pain or sensory disturbances between the surgical and nonsurgical treatment groups, although the surgical group had a small advantage in muscle strength",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent two-year randomized trial of 63 patients with cervical radiculopathy due to disc disease assigned patients to either anterior cervical discectomy and fusion combined with physical therapy or physical therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/33\">",
"     33",
"    </a>",
"    ]. There was no significant difference between the groups for any of the outcome measures, which included neck active range of motion, neck muscle endurance, and hand-related function. Patients in both groups improved over time to a similar degree on these measures, though function remained below normative values.",
"   </p>",
"   <p>",
"    In contrast the evidence from these randomized trials, the findings from two prospective observational studies suggest that surgery is beneficial for patients with cervical radiculopathy, with substantial improvement in pain and weakness in approximately 75 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. These studies did not document the percentage of patients with complete pain resolution. Earlier observational studies had found that improved outcome with surgery was more likely in patients with radicular pain than those without radicular pain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to cervical radiculopathy, the benefit of surgery for the treatment of cervical myelopathy has not been established, and data are sparse. A few small randomized controlled trials have found that surgery did not improve long-term outcome compared with conservative management [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/32,36,37\">",
"     32,36,37",
"    </a>",
"    ]. However, surgery was beneficial in one of these studies at two years for a subgroup of 12 patients who had severe disability at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Indications for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proposed indications for surgery in patients with cervical radiculopathy are unremitting radicular pain despite six to eight weeks of conservative treatment, progressive motor weakness, or the presence of myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More stringent indications for surgery have also been proposed that require the presence of all of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms and signs of cervical radiculopathy (ie, nerve root dysfunction, pain, or both)",
"     </li>",
"     <li>",
"      Evidence of cervical nerve root compression by magnetic resonance imaging (MRI) or computed tomography (CT) myelography at the appropriate side and level(s) to explain the clinical symptoms and signs",
"     </li>",
"     <li>",
"      Persistence of radicular pain despite nonsurgical therapy for at least six to 12 weeks or progressive motor weakness that impairs function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with myelopathy, the more stringent indications for surgery require the following [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neuroimaging evidence of cervical spinal cord compression",
"     </li>",
"     <li>",
"      Objective motor or sensory signs of myelopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest surgery only for patients who meet these stringent criteria for cervical radiculopathy or myelopathy. As part of a presurgical evaluation, flexion and extension plain films are necessary to assess the stability of the cervical spine [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/38\">",
"     38",
"    </a>",
"    ]. There are two main surgical approaches: anterior cervical discectomy and fusion, and posterior laminoforaminotomy. Artificial disc replacement is a surgical strategy that we regard as investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anterior cervical discectomy and fusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior cervical discectomy and fusion (ACDF) is the most commonly used decompressive procedure in the cervical spine.",
"   </p>",
"   <p>",
"    The advantages of ACDF are that it requires little manipulation of the spinal cord or cervical roots and allows for removal of both lateral and midline disc herniation and osteophytes. Disadvantages include a small risk of damage to the carotid artery, trachea, esophagus, or recurrent laryngeal nerve, and alteration of the architecture of the spine. Some authors suggest that ACDF may lead to further degenerative changes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Posterior laminoforaminotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A posterior surgical approach may be used when a single lateral disc herniation is present. A posterior laminoforaminotomy (POF) is frequently performed, although many variations have been described. Midline pathology is not easily accessible with POF. As a result, this approach is not useful in patients with midline disc herniation or osteophytes.",
"   </p>",
"   <p>",
"    The main advantages of POF are that it involves no alteration of the architecture of the cervical spine and no risk of damage to anterior neck structures. The main disadvantage is that there may be more postoperative pain with POF than with ACDF, although this is controllable with medications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Artificial disc replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artificial cervical disc replacement surgery is a developing technique for the treatment of single level cervical radiculopathy that has been used in situations when an anterior cervical discectomy and fusion (ACDF) would otherwise be appropriate. One randomized trial with 115 patients found that artificial disc replacement compared favorably to ACDF at two-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/41\">",
"     41",
"    </a>",
"    ]. There are, however, few rigorous studies, and the long-term durability of the devices that have been developed is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of surgery for cervical radiculopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myelopathy are uncommon, but include spinal cord injury (&lt;1 percent of cases), nerve root injury (2 to 3 percent), and instrumentation or device failure (&le;4 percent). Additional complications seen with anterior surgical approaches in retrospective studies include transient dysphagia (10 percent), recurrent laryngeal nerve injury (2 to 3 percent), esophageal perforation (&lt;1 percent), vertebral artery injury (&lt;1 percent), and superficial wound infection (&lt;1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17144/abstract/4,34,35,42-45\">",
"     4,34,35,42-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/31/23026?source=see_link\">",
"       \"Patient information: Neck pain (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/8/32898?source=see_link\">",
"       \"Patient information: Radiculopathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=see_link\">",
"       \"Patient information: Neck pain (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimum treatment of compressive cervical radiculopathy is the subject of continued debate, and there is little convincing evidence that any treatment improves upon the natural history of the condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited data suggest that most patients with compressive cervical radiculopathy improve without specific treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with cervical radiculopathy who have clear radicular pain and symptoms of paresthesia, numbness, or nonprogressive neurologic deficits, we suggest conservative therapy as initial treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically start treatment with oral analgesics (eg, NSAIDs) and avoidance of provocative activities, and add a short course of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      if pain is severe. Once the pain is tolerable, we initiate physical therapy with exercise and gradual mobilization. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Conservative therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of cervical radiculopathy may recur in up to one-third of patients after initial improvement. Conservative management should be reemployed if symptoms recur unless a significant motor deficit or myelopathy is present. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Refractory or progressive symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with confirmed cervical radiculopathy who have severe or disabling pain despite a reasonable course of conservative therapy, and who do not have a progressively worsening neurologic deficit, we suggest the use of epidural steroid injections rather than surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The injections should be performed by experienced centers and interventionalists under fluoroscopic guidance using test contrast injection to identify accidental vessel injection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Epidural glucocorticoid injections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of surgery for the treatment of cervical radiculopathy has not been clearly established, and data from controlled trials are sparse. For patients with cervical radiculopathy who have all of the following conditions, we suggest surgery rather than nonsurgical therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Symptoms and signs of cervical radiculopathy",
"     </li>",
"     <li>",
"      Cervical nerve root compression by MRI or CT myelography at the appropriate side and level(s)",
"     </li>",
"     <li>",
"      Persistence of radicular pain despite nonsurgical therapy for at least 6 to 12 weeks, or progressive motor weakness that impairs function (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Surgery'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As with cervical radiculopathy, the benefit of surgery for the treatment of cervical myelopathy has not been established, and controlled trial data are sparse. For patients with neuroimaging evidence of cervical spinal cord compression, objective motor or sensory signs of myelopathy, and progressive weakness or disability, we suggest surgery rather than nonsurgical therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/1\">",
"      LEES F, TURNER JW. NATURAL HISTORY AND PROGNOSIS OF CERVICAL SPONDYLOSIS. Br Med J 1963; 2:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/2\">",
"      Radhakrishnan K, Litchy WJ, O'Fallon WM, Kurland LT. Epidemiology of cervical radiculopathy. A population-based study from Rochester, Minnesota, 1976 through 1990. Brain 1994; 117 ( Pt 2):325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/3\">",
"      Ellenberg MR, Honet JC, Treanor WJ. Cervical radiculopathy. Arch Phys Med Rehabil 1994; 75:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/4\">",
"      Carette S, Fehlings MG. Clinical practice. Cervical radiculopathy. N Engl J Med 2005; 353:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/5\">",
"      Kuijper B, Tans JT, Beelen A, et al. Cervical collar or physiotherapy versus wait and see policy for recent onset cervical radiculopathy: randomised trial. BMJ 2009; 339:b3883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/6\">",
"      MARTIN GM, CORBIN KB. An evaluation of conservative treatment for patients with cervical disk syndrome. Arch Phys Med Rehabil 1954; 35:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/7\">",
"      Honet JC, Puri K. Cervical radiculitis: treatment and results in 82 patients. Arch Phys Med Rehabil 1976; 57:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/8\">",
"      Arnasson O, Carlsson CA, Pellettieri L. Surgical and conservative treatment of cervical spondylotic radiculopathy and myelopathy. Acta Neurochir (Wien) 1987; 84:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/9\">",
"      Saal JS, Saal JA, Yurth EF. Nonoperative management of herniated cervical intervertebral disc with radiculopathy. Spine (Phila Pa 1976) 1996; 21:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/10\">",
"      Fast A, Parikh S, Marin EL. The shoulder abduction relief sign in cervical radiculopathy. Arch Phys Med Rehabil 1989; 70:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/11\">",
"      Goldie I, Landquist A. Evaluation of the effects of different forms of physiotherapy in cervical pain. Scand J Rehabil Med 1970; 2:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/12\">",
"      Klaber Moffett JA, Hughes GI, Griffiths P. An investigation of the effects of cervical traction. Part 1: Clinical effectiveness. Clin Rehabil 1990; 4:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/13\">",
"      Pain in the neck and arm: a multicentre trial of the effects of physiotherapy, arranged by the British Association of Physical Medicine. Br Med J 1966; 1:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/14\">",
"      van der Heijden GJ, Beurskens AJ, Koes BW, et al. The efficacy of traction for back and neck pain: a systematic, blinded review of randomized clinical trial methods. Phys Ther 1995; 75:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/15\">",
"      Graham N, Gross AR, Goldsmith C, Cervical Overview Group. Mechanical traction for mechanical neck disorders: a systematic review. J Rehabil Med 2006; 38:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/16\">",
"      Colachis SC Jr, Strohm BR. Effect of duration of intermittent cervical traction on vertebral separation. Arch Phys Med Rehabil 1966; 47:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/17\">",
"      Cicala RS, Thoni K, Angel JJ. Long-term results of cervical epidural steroid injections. Clin J Pain 1989; 5:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/18\">",
"      Slipman CW, Lipetz JS, Jackson HB, et al. Therapeutic selective nerve root block in the nonsurgical treatment of atraumatic cervical spondylotic radicular pain: a retrospective analysis with independent clinical review. Arch Phys Med Rehabil 2000; 81:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/19\">",
"      Bush K, Hillier S. Outcome of cervical radiculopathy treated with periradicular/epidural corticosteroid injections: a prospective study with independent clinical review. Eur Spine J 1996; 5:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/20\">",
"      Vall&eacute;e JN, Feydy A, Carlier RY, et al. Chronic cervical radiculopathy: lateral-approach periradicular corticosteroid injection. Radiology 2001; 218:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/21\">",
"      Anderberg L, Annertz M, Persson L, et al. Transforaminal steroid injections for the treatment of cervical radiculopathy: a prospective and randomised study. Eur Spine J 2007; 16:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/22\">",
"      Rathmell JP, Aprill C, Bogduk N. Cervical transforaminal injection of steroids. Anesthesiology 2004; 100:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/23\">",
"      Wagner AL. CT fluoroscopic-guided cervical nerve root blocks. AJNR Am J Neuroradiol 2005; 26:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/24\">",
"      Kranz PG, Raduazo PA. Technique for CT fluoroscopy-guided cervical interlaminar steroid injections. AJR Am J Roentgenol 2012; 198:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/25\">",
"      Malhotra G, Abbasi A, Rhee M. Complications of transforaminal cervical epidural steroid injections. Spine (Phila Pa 1976) 2009; 34:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/26\">",
"      Scanlon GC, Moeller-Bertram T, Romanowsky SM, Wallace MS. Cervical transforaminal epidural steroid injections: more dangerous than we think? Spine (Phila Pa 1976) 2007; 32:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/27\">",
"      Santiago-Palma J, Vallejo R, Kornick C, Barna S. Are cervical nerve root blocks \"safe and effective\"? AJNR Am J Neuroradiol 2005; 26:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/28\">",
"      Mendelson J, Muppidi S, Silberstein S. Multiple intracerebral hemorrhages after cervical epidural injections. Neurology 2008; 70:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/29\">",
"      Rozin L, Rozin R, Koehler SA, et al. Death during transforaminal epidural steroid nerve root block (C7) due to perforation of the left vertebral artery. Am J Forensic Med Pathol 2003; 24:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/30\">",
"      Ziai WC, Ardelt AA, Llinas RH. Brainstem stroke following uncomplicated cervical epidural steroid injection. Arch Neurol 2006; 63:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/31\">",
"      Nikolaidis I, Fouyas IP, Sandercock PA, Statham PF. Surgery for cervical radiculopathy or myelopathy. Cochrane Database Syst Rev 2010; :CD001466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/32\">",
"      Persson LC, Moritz U, Brandt L, Carlsson CA. Cervical radiculopathy: pain, muscle weakness and sensory loss in patients with cervical radiculopathy treated with surgery, physiotherapy or cervical collar. A prospective, controlled study. Eur Spine J 1997; 6:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/33\">",
"      Peolsson A, S&ouml;derlund A, Engquist M, et al. Physical function outcome in cervical radiculopathy patients after physiotherapy alone compared with anterior surgery followed by physiotherapy: a prospective randomized study with a 2-year follow-up. Spine (Phila Pa 1976) 2013; 38:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/34\">",
"      Hacker RJ, Cauthen JC, Gilbert TJ, Griffith SL. A prospective randomized multicenter clinical evaluation of an anterior cervical fusion cage. Spine (Phila Pa 1976) 2000; 25:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/35\">",
"      Casha S, Fehlings MG. Clinical and radiological evaluation of the Codman semiconstrained load-sharing anterior cervical plate: prospective multicenter trial and independent blinded evaluation of outcome. J Neurosurg 2003; 99:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/36\">",
"      Bednar&iacute;k J, Kadanka Z, Voh&aacute;nka S, et al. The value of somatosensory- and motor-evoked potentials in predicting and monitoring the effect of therapy in spondylotic cervical myelopathy. Prospective randomized study. Spine (Phila Pa 1976) 1999; 24:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/37\">",
"      Kadanka Z, Bednar&iacute;k J, Voh&aacute;nka S, et al. Conservative treatment versus surgery in spondylotic cervical myelopathy: a prospective randomised study. Eur Spine J 2000; 9:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/38\">",
"      Storm PB, Chou D, Tamargo RJ. Surgical management of cervical and lumbosacral radiculopathies: indications and outcomes. Phys Med Rehabil Clin N Am 2002; 13:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/39\">",
"      Wirth FP, Dowd GC, Sanders HF, Wirth C. Cervical discectomy. A prospective analysis of three operative techniques. Surg Neurol 2000; 53:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/40\">",
"      Zeidman SM, Ducker TB. Posterior cervical laminoforaminotomy for radiculopathy: review of 172 cases. Neurosurgery 1993; 33:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/41\">",
"      Sasso RC, Smucker JD, Hacker RJ, Heller JG. Artificial disc versus fusion: a prospective, randomized study with 2-year follow-up on 99 patients. Spine (Phila Pa 1976) 2007; 32:2933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/42\">",
"      Edwards CC 2nd, Heller JG, Murakami H. Corpectomy versus laminoplasty for multilevel cervical myelopathy: an independent matched-cohort analysis. Spine (Phila Pa 1976) 2002; 27:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/43\">",
"      Fountas KN, Kapsalaki EZ, Nikolakakos LG, et al. Anterior cervical discectomy and fusion associated complications. Spine (Phila Pa 1976) 2007; 32:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/44\">",
"      Inamasu J, Guiot BH. Iatrogenic vertebral artery injury. Acta Neurol Scand 2005; 112:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17144/abstract/45\">",
"      Neo M, Fujibayashi S, Miyata M, et al. Vertebral artery injury during cervical spine surgery: a survey of more than 5600 operations. Spine (Phila Pa 1976) 2008; 33:779.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5263 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17144=[""].join("\n");
var outline_f16_47_17144=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Compressive radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Triage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Noncompressive radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NONSURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Conservative therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Exercise therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cervical traction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Refractory or progressive symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Epidural glucocorticoid injections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Indications for surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anterior cervical discectomy and fusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Posterior laminoforaminotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Artificial disc replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5263\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5263|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/50/807\" title=\"figure 1\">",
"      Cervical epidural injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5263|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/34/16939\" title=\"table 1\">",
"      Causes of noncompressive radiculopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=related_link\">",
"      Clinical features and diagnosis of cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=related_link\">",
"      Patient information: Neck pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/31/23026?source=related_link\">",
"      Patient information: Neck pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/8/32898?source=related_link\">",
"      Patient information: Radiculopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=related_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_47_17145="Histology normal breast tissue";
var content_f16_47_17145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histology of normal breast tissue of a premenopausal woman",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 534px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper panel, low power photomicrograph, showing several lobules and a few extralobular ducts (arrow); lower panel, high power photomicrograph of several acini of a lobule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schnitt SJ. Normal anatomy and development, In: Atlas of Breast Cancer, Hayes, DF (Ed). Harcourt Publishers Ltd. 2000, p.3.3. Copyright &copy; 2000 Mosby.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17145=[""].join("\n");
var outline_f16_47_17145=null;
var title_f16_47_17146="Laser and light therapy for cutaneous vascular lesions";
var content_f16_47_17146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laser and light therapy for cutaneous vascular lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/47/17146/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17146/contributors\">",
"     Kristen M Kelly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/47/17146/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17146/contributors\">",
"     Jeffrey S Dover, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17146/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/47/17146/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/47/17146/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/47/17146/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10061257\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lasers and intense pulsed light (IPL) are used for the treatment of multiple cutaneous vascular lesions including telangiectasias, port wine stains (PWS), and infantile hemangiomas. During treatment, the absorption of light energy by intravascular oxyhemoglobin leads to heating and coagulation of lesional blood vessels. The responses of vascular lesions to therapy are influenced by the type of light source used, the clinical characteristics of the target lesion, and patient-specific factors (eg, skin color, patient age).",
"   </p>",
"   <p>",
"    Although laser and IPL therapy can result in clinical benefits, treatment is not innocuous. Cutaneous and ocular damage can occur if clinicians are not vigilant. The use of appropriate equipment settings, skin cooling mechanisms, and other safety measures minimize the occurrence of adverse events due to treatment.",
"   </p>",
"   <p>",
"    The types of lasers used in the treatment of vascular lesions as well as the efficacy and clinical use of lasers for the treatment of PWS, hemangiomas, and telangiectasias will be discussed here. The general principles of medical lasers, the principles of light therapy for the treatment of skin, and laser and light therapy for lower extremity telangiectasias and veins are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=see_link\">",
"     \"Basic principles of medical lasers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12728454\">",
"    <span class=\"h1\">",
"     PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The theory of selective photothermolysis describes the method through which lasers or intense pulsed light (IPL) can be used to selectively destroy specific targets in the skin while minimizing damage to other cutaneous structures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/1\">",
"     1",
"    </a>",
"    ]. In concordance with this theory, light energy must be delivered in a manner that results in preferential absorption of light by light-absorbing molecules (chromophores) located within the target. The absorption of light energy by chromophores leads to heating and coagulation of the target. In order to limit collateral damage, the diffusion of heat to adjacent tissues must also be minimized. The principles of laser and light therapy for cutaneous lesions are reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major chromophore targeted during therapy of vascular lesions is oxyhemoglobin. Significant light absorption by oxyhemoglobin occurs in the range of yellow and green light; peak absorption occurs at 418, 542, and 577 nm [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/1\">",
"     1",
"    </a>",
"    ]. A lower peak of light absorption by oxyhemoglobin occurs in the near-infrared light range. Thus, lasers that emit wavelengths of light near the primary absorption peaks of oxyhemoglobin, such as the 585 or 595 nm pulsed dye and the 532 nm frequency-doubled neodymium:yttrium aluminum garnet (Nd:YAG) lasers, are often favored for the treatment of vascular lesions. Infrared-range lasers (1064 nm Nd:YAG, alexandrite, or diode) can also be effective for this indication, but are associated with a greater risk for tissue damage and ulceration.",
"   </p>",
"   <p>",
"    The potential for light absorption by melanin, another chromophore ubiquitously present in the skin, must be considered prior to the treatment of vascular lesions. Light absorption by melanin progressively increases as wavelengths of light decrease, leading to a relatively higher risk of dyspigmentation secondary to melanin absorption with the use of shorter wavelengths of light. This is of particular concern in patients with dark skin, in whom epidermal melanin is abundant. Epidermal skin cooling techniques and adjustments to laser settings can be used to reduce the incidence of adverse effects secondary to epidermal melanin absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/2\">",
"     2",
"    </a>",
"    ]. Absorption of light by epidermal melanin can also affect the efficacy of treatment through reducing the amount of light that reaches vessels in the dermis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999161#H31999161\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Skin cooling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the absorption of light by superficial chromophores can influence the amount of light that reaches deep tissues, the wavelength of emitted light is a critical factor for determining the depth to which light penetrates the skin. Longer wavelengths of light are capable of penetrating the skin more deeply than shorter wavelengths. As an example, in a patient with Fitzpatrick skin type II (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ), light with a 585 nm wavelength may penetrate roughly 0.65 mm into the skin, while 595 nm may reach a depth of approximately 1 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999082#H31999082\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Wavelength'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because short wavelengths of light penetrate the skin only superficially, long wavelengths, such as those in the near-infrared range, are required to reach vessels that are deeper than the upper dermis. This feature plus a relatively high risk of light absorption by epidermal melanin are the primary reasons that lasers with wavelengths near the 418 nm peak of oxyhemoglobin light absorption are generally avoided in the treatment of vascular lesions. Since target vascular lesions often contain vessels at variable depths, using lasers of different wavelengths over the course of several treatments can be useful for achieving desired clinical effects.",
"   </p>",
"   <p>",
"    Other laser settings that influence the efficacy of laser and light therapy for vascular lesions include the pulse duration, fluence (energy delivered per unit area), and spot size. Pulse durations equal to or shorter than the vessel thermal relaxation time (time required for a target to lose accumulated heat) are often used to reduce the risk of damage to surrounding structures. Pulse durations that exceed a structure&rsquo;s thermal relaxation time allow the diffusion of heat to adjacent structures, increasing the risk for collateral damage in the skin. The thermal relaxation times for vessels in port wine stains (typically 10 to 300 &mu;m in diameter) range from 1 to 10 ms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999090#H31999090\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Pulse duration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pulse duration also affects clinical responses to treatment. Short pulse durations (eg, 0.45 ms) often result in rapid heating and rupture of target vessels, contributing to the appearance of post-treatment purpura, which some cosmetic patients treated for telangiectases find undesirable. In contrast, long pulse durations deliver light energy over a longer period and allow slow heating of target vessels, preventing sudden vessel rupture and reducing the risk of purpura. Long pulses may also be useful for the destruction of large vessels; large structures lose heat slowly, and the accumulation of heat that occurs over long pulse durations may facilitate coagulation of larger vessels.",
"   </p>",
"   <p>",
"    The appropriate laser or IPL setting for the amount of energy delivered to the skin per unit area (fluence) is an important factor for efficacious and safe treatment of vascular lesions. The energy delivered must be sufficient for the chromophore to absorb enough heat to induce vessel coagulation, but should not reach levels that induce excessive damage to the skin. Skin cooling mechanisms can be used to reduce the risk of skin damage associated with the use of high fluences [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999097#H31999097\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Fluence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term &ldquo;spot size&rdquo; is used to describe the size of the area through which light is delivered. Large spot sizes minimize scattering of light as it enters the skin, allowing more light to reach the target structure. Large spot sizes also facilitate the treatment of large lesions. A small spot size may be preferred for the treatment of a small, focal telangiectasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H31999113#H31999113\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Spot size'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12728466\">",
"    <span class=\"h1\">",
"     VASCULAR LASERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of lasers are used for the treatment of vascular lesions. Specific laser characteristics determine the most appropriate clinical settings for use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113212014\">",
"    <span class=\"h2\">",
"     Yellow and green light lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;High peaks for the absorption of light by oxyhemoglobin occur within the range of yellow and green light. Thus, lasers that emit light in this range are commonly used for the treatment of vascular lesions. However, the restricted depth of penetration of light emitted from these lasers may limit their efficacy for the destruction of vessels located below the superficial dermis. Dyspigmentation is also a risk associated with the use of these lasers, given the relatively high absorption of light in this range by melanin. (See",
"    <a class=\"local\" href=\"#H12728454\">",
"     'Principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3923207\">",
"    <span class=\"h3\">",
"     Pulsed dye laser",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flashlamp-pumped pulsed dye laser (PDL, 585 to 600 nm) has a long history of safe and effective use for vascular lesions. Traditional 577 nm PDLs are commonly used with pulse durations of approximately 0.45 ms, which is much shorter than the thermal relaxation time of small, superficial vessels (1 to 10 ms). This minimizes collateral damage in the skin. However, use of short pulse durations often leads to rapid heating of vessels and vessel rupture, contributing to the appearance of post-treatment temporary purpura. Long-pulse PDLs (595 to 600 nm, pulse duration &ge;1.5 ms) slowly heat target vessels, and can be used without the formation of purpura. However, subpurpuric protocols with long-pulse PDLs may be less effective for the treatment of telangiectasias [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], and clinical experience suggests similar effects in the treatment of port wine stains (PWS). (See",
"    <a class=\"local\" href=\"#H461968721\">",
"     'Clinical use'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12728497\">",
"    <span class=\"h3\">",
"     Frequency-doubled Nd:YAG (KTP) lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency-doubled Nd:YAG laser, also known as the potassium titanyl phosphate (KTP) laser, consists of light from an Nd:YAG laser that is passed through a KTP crystal. The wavelength of this laser is 532 nm, near the 542 nm absorption peak of oxyhemoglobin. Pulse durations of frequency-doubled Nd:YAG lasers are in the millisecond range, which allows treatment of vascular lesions without the formation of purpura. However, the short wavelength results in a lower depth of skin penetration compared with PDLs. Light emitted by frequency-doubled Nd:YAG lasers is also absorbed to a greater extent by melanin, augmenting the risk of dyspigmentation, particularly in patients with dark skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113212036\">",
"    <span class=\"h2\">",
"     Near-infrared lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A secondary, lower peak for the absorption of light by oxyhemoglobin occurs in the near-infrared range (720 to 1200 nm). Alexandrite (755 nm), diode (800 to 980 nm), and long-pulsed Nd:YAG (1064 nm) lasers are used to capitalize on this property, and can be effective for the treatment of vascular lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/7\">",
"     7",
"    </a>",
"    ]. The relatively long wavelengths of light emitted by these lasers penetrate the skin to greater depths than is possible with PDL or frequency-doubled Nd:YAG lasers. Thus, these lasers are generally utilized when vessels deep in the skin are targeted. Pulse durations of these near-infrared lasers are in the millisecond range, facilitating the treatment of larger vessels.",
"   </p>",
"   <p>",
"    A disadvantage of near-infrared lasers is that the relatively lower absorption of light by oxyhemoglobin in this light range demands the use of higher fluences during treatment of vascular lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/8\">",
"     8",
"    </a>",
"    ]. This leads to a greater risk of inadvertent scarring compared with PDLs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113212064\">",
"    <span class=\"h2\">",
"     Dual wavelength lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dual wavelength lasers including an",
"    <span class=\"nowrap\">",
"     Nd:YAG/KTP",
"    </span>",
"    laser that emits 1064 and 532 nm light simultaneously, and a sequentially firing 595 and 1064 nm dual wavelength device have been used for the treatment of resistant vascular lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3923257\">",
"    <span class=\"h2\">",
"     Intense pulsed light",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intense pulsed light sources (IPLs) are non-laser flashlamp devices that produce incoherent, broad bands of light ranging from 515 to 1200 nm. Selective light filters can be used to restrict the emitted wavelengths to a narrower range for a more specific tissue effect.",
"   </p>",
"   <p>",
"    IPLs have versatility, as they generate a wide range of light wavelengths, pulse durations, and pulse sequences. However, treatment of some types of vascular lesions with IPL can require more sessions than laser therapy to achieve the same clinical effect. (See",
"    <a class=\"local\" href=\"#H368860431\">",
"     'Other lasers and IPL'",
"    </a>",
"    below.) Another potentially detrimental feature of IPL is the emission of wavelengths of light highly absorbed by epidermal melanin, which leads to a relatively high risk of pigmentary adverse effects. Use of skin cooling techniques during IPL therapy is essential for reducing this risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10061356\">",
"    <span class=\"h1\">",
"     PORT WINE STAINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Port wine stains (PWS) are congenital capillary malformations characterized by erythematous to violaceous patches (",
"    <a class=\"graphic graphic_picture graphicRef73343 graphicRef60560 graphicRef54078 \" href=\"UTD.htm?23/21/23897\">",
"     picture 1A-C",
"    </a>",
"    ). Lesions may be extensive, and papular and nodular components often develop during adulthood. PWS can lead to psychological distress in some patients, and complications such as nodules, bleeding, pyogenic granulomas, and tissue hypertrophy can occur in mature lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=see_link&amp;anchor=H5#H5\">",
"     \"Vascular lesions in the newborn\", section on 'Port wine stains'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laser therapy is the standard of care for the treatment of PWS. Previously established treatments, such as cryotherapy, electrocautery and excision result in unacceptable scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2421284\">",
"    <span class=\"h2\">",
"     Efficacy of PDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsed dye lasers (PDLs) are the lasers used most commonly for the treatment of PWS. While other lasers have also been used for treatment of PWS, the PDL has a long history of safety and efficacy. (See",
"    <a class=\"local\" href=\"#H368860431\">",
"     'Other lasers and IPL'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Multiple treatments are usually required to achieve maximum lightening of PWS, and complete clearance is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In one study of 76 patients with PWS, overall clinical improvement of 79 percent was achieved after an average of nine treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristics that may indicate a lower likelihood for a complete response include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Older child or adult [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/12,16-18\">",
"       12,16-18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Location on trunk or extremity [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Location on central face (medial cheek, upper lip, nose) rather than on other facial areas [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Violaceous or nodular lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175203890\">",
"    <span class=\"h3\">",
"     Patient age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal timing of treatment of PWS is controversial. Although an uncontrolled study of 89 patients with PWS treated with PDL found no difference in the degree of improvement in patients of varying ages (0 to 31 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/22\">",
"     22",
"    </a>",
"    ], the results of multiple studies suggest that very young children may require fewer treatments for lesion clearance and may be more likely to achieve greater overall lightening:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an uncontrolled study of 73 children treated with a 577 or 585 nm PDL for PWS, those aged three months to six years exhibited better responses after the first treatment than those aged 7 to 14 years (55 versus 44 percent lesion lightening) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an uncontrolled study of 35 children (age 3 months to 14 years) treated with a 577 nm PDL, children under the age of seven required fewer treatments for optimal response than older children (5.8 &plusmn;1.1 versus 7.1&plusmn;1.1 treatments) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 83 children with facial lesions treated with a 577 or 585 nm PDL, patients who were treated while under the age of one year were more likely to have complete clearance of PWS with treatment than older patients (32 versus 18 percent achieved complete clearance) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/17\">",
"       17",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      In an uncontrolled study of 91 children with facial PWS treated with a 585 nm PDL, the mean decrease in lesion size after the first five treatments was greater in patients less than one year old than in those aged one to six years or greater than six years (63, 48, and 54 percent reductions in lesion size, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment also appears to be well-tolerated in young infants:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 49 infants less than or equal to six months of age, treatment with a 595 nm PDL with dynamic cooling led to an average percentage of lesion clearance of 89 percent. No patients developed atrophy or scarring [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 12 children ages 6 to 30 weeks treated with PDL, 10 had greater than 50 percent lightening of PWS after 2.9 &plusmn; 1.4 treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/24\">",
"       24",
"      </a>",
"      ]. No patients experienced scarring, atrophy, or dyspigmentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Greater efficacy of treatment in young children may be related to the presence of thinner skin and smaller lesional vessels in this population when compared with older individuals. PWS often develop thickening and nodularity as patients age, and lesions with these changes may be more difficult to treat [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/11,25-27\">",
"     11,25-27",
"    </a>",
"    ]. The relatively smaller size of lesions in young children may also be a factor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. We typically aim to begin treatment of PWS within the first three months of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175203897\">",
"    <span class=\"h3\">",
"     Lesion location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesion location may affect the response to treatment. In a retrospective study of 259 adults and children with PWS on the head and neck, centrofacial lesions (medial cheek, upper lip, and nose) responded less favorably to treatment than other areas of the face (mean percentage lightening 71 versus 82 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/20\">",
"     20",
"    </a>",
"    ]. Lesions involving the V2 dermatome also responded less favorably than other dermatomes of the face and neck (mean percentage lightening 74 versus 82 percent).",
"   </p>",
"   <p>",
"    A subsequent uncontrolled study of 91 patients supported the finding that centrofacial PWS tend to respond less favorably than lesions in other sites; percentage decreases in the size of forehead, peripheral facial, and centrofacial lesions following 577 or 585 nm PDL therapy were 100, 58, and 48 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175203904\">",
"    <span class=\"h3\">",
"     Lesion characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular, or very large lesions may exhibit increased resistance to PDL therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/17,18,21\">",
"     17,18,21",
"    </a>",
"    ]. Treatment with other types of lasers can be beneficial in the management of resistant lesions. (See",
"    <a class=\"local\" href=\"#H368860431\">",
"     'Other lasers and IPL'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175204195\">",
"    <span class=\"h3\">",
"     Dark skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of PWS in patients with dark skin presents specific challenges. Absorption of laser energy by epidermal melanin inhibits light delivery to underlying PWS vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, the potential for hypopigmentation or hyperpigmentation as a consequence of laser therapy is more likely, and once present, is often more apparent in patients with dark skin. Use of appropriate laser settings and epidermal cooling techniques helps to minimize this risk. (See",
"    <a class=\"local\" href=\"#H12728550\">",
"     'Clinical use'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175204202\">",
"    <span class=\"h3\">",
"     Long term efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions may recur after treatment. In a 10-year follow-up study of 51 patients treated with PDL for PWS, lesions were significantly darker at follow-up than at the time of the last treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/28\">",
"     28",
"    </a>",
"    ]. However, treated lesions remained significantly lighter than they were prior to the start of treatment, supporting the existence of long-lasting beneficial effects of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12728550\">",
"    <span class=\"h2\">",
"     Clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although PDLs are the standard of care for PWS, a lack of studies evaluating the efficacy of specific laser parameters, the continued evolution of laser technology, and variations in patient skin color and lesion characteristics have precluded the development of standardized treatment guidelines. In general, appropriate parameters for PDL treatment of PWS include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wavelength: 585 to 600 nm",
"     </li>",
"     <li>",
"      Pulse duration: 0.45 to 10 msec",
"     </li>",
"     <li>",
"      Fluence: 4.5 to 12",
"      <span class=\"nowrap\">",
"       J/cm",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Spot size: at least 7 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 595 nm PDL with variable pulse durations has become the laser most frequently used for the treatment of PWS. Compared with the traditional 585 nm PDL, light from the 595 nm PDL is able to penetrate the skin to a slightly greater depth. In addition, the ability to deliver pulse durations in the millisecond range (typically 1.5 to 6 ms) may facilitate the destruction of larger vessels. Despite these theoretical advantages of the 595 PDL, studies conflict on whether treatment with the 595 nm PDL is clinically more effective than the 585 nm short-pulsed laser [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. However, a case report and the results of a small prospective study suggest that some patients who have failed to improve adequately with the 585 nm PDL benefit from treatment with a 595 nm long-pulsed PDL [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate initial PDL fluence settings vary. Factors such as patient age, skin color, lesion morphology, lesion location, laser type, and laser spot size determine the correct fluence setting. Adequate epidermal cooling techniques reduce the risk of epidermal damage and scarring and allow the use of higher fluences in the hands of experienced clinicians. Epidermal cooling is particularly important in patients with dark skin, in whom inadequate cooling is likely to result in hyperpigmentation or hypopigmentation.",
"   </p>",
"   <p>",
"    When treating a PWS on the cheek in an older child or adult with Fitzpatrick skin phototype II (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ), appropriate initial fluence settings for a 595 long-pulsed PDL with a 10 mm spot size and a dynamic epidermal cooling mechanism generally range from 5.5 to 7",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Lower initial fluences are typically used for young children, individuals with dark skin, and lesions in areas at higher risk for cutaneous damage, such as the eyelid. Depending on the response to treatment, fluences can be increased by 0.5",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with subsequent treatments if desired results are not achieved and no adverse effects are noted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large spot sizes (&ge;7 mm) are generally preferred, as they minimize light scattering, and thus allow greater delivery of light energy to target structures. Large spot sizes also facilitate the treatment of large PWS. Although the impact of patient-positioning during treatment has not been specifically studied, we typically place the treatment site in a dependent position (eg, Trendelenburg position for facial lesions) immediately prior to treatment to increase local blood volume, which theoretically may increase the size of the vascular target.",
"   </p>",
"   <p>",
"    Treatment should be performed in a methodical fashion, with care to maintain the position of the laser perpendicular to the surface of the skin (",
"    <a class=\"graphic graphic_picture graphicRef80239 \" href=\"UTD.htm?25/5/25680\">",
"     picture 2",
"    </a>",
"    ). This also ensures the proper delivery of cooling when using lasers with integrated cooling technology. Overlapping pulses by approximately 10 percent reduces the amount of untreated space [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency with which treatments are administered varies in the literature, ranging from every few weeks to every few months. We typically administer PDL treatments every four to six weeks for facial lesions. We use longer intervals (six to eight weeks) for patients with dark skin types (Fitzpatrick phototype IV or higher) or for lesions on the extremities, since postinflammatory hyperpigmentation is more common and lasts longer in these settings. Longer time intervals between sessions allow for treatment and improvement of hyperpigmentation, which can reduce treatment efficacy. (See",
"    <a class=\"local\" href=\"#H368860500\">",
"     'Precautions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment can be continued until lesions clear or until no further improvement is noted with optimal PDL settings, typically between 3 and more than 15 sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/2\">",
"     2",
"    </a>",
"    ]. Variations in vessel size and depth within a particular lesion promote the value of utilizing more than one set of PDL parameters over the course of treatment of a PWS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retreating areas during the same treatment session (multiple pass technique) may also be beneficial for facial lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/36\">",
"     36",
"    </a>",
"    ]. The pulse duration or laser wavelength can also be altered with subsequent passes. Multiple passes should only be performed by clinicians experienced in laser treatment due to an increased risk for scarring. The risk for scarring with this technique may be higher for lesions in other locations.",
"   </p>",
"   <p>",
"    Local anesthesia or general anesthesia may be used in select cases. (See",
"    <a class=\"local\" href=\"#H10061407\">",
"     'Anesthesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368860500\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue response should be watched closely with initial pulses and throughout treatment. Immediate purpura is the desired tissue response during PDL treatment for PWS (",
"    <a class=\"graphic graphic_picture graphicRef59618 \" href=\"UTD.htm?9/60/10176\">",
"     picture 3",
"    </a>",
"    ). PDL-induced purpura typically resolves within 10 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/37\">",
"     37",
"    </a>",
"    ]. The appearance of a gray or white color on the skin after the delivery of a laser pulse denotes epidermal injury and should be avoided.",
"   </p>",
"   <p>",
"    Local edema and sunburn-like pain are common after treatment. Elevation, ice packs, nonprescription oral analgesics, and bland topical emollients are useful for decreasing patient discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/2\">",
"     2",
"    </a>",
"    ]. Post-treatment sun avoidance should be recommended to reduce the risk of subsequent hyperpigmentation. For patients with skin color classified as Fitzpatrick phototype III or higher as well as patients with lighter skin who develop post-treatment hyperpigmentation (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 1",
"    </a>",
"    ), we typically prescribe daily application of a bleaching cream, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    4%, between treatment sessions to further decrease the risk of this adverse effect. Daily application of hydroquinone should begin immediately after the resolution of purpura, and should continue until the next treatment. Because irritant dermatitis can also induce hyperpigmentation, we decrease the frequency of application or discontinue topical bleaching agents in patients who develop skin irritation secondary to these drugs.",
"   </p>",
"   <p>",
"    Blistering, scarring, cutaneous atrophy, and hypopigmentation are additional potential adverse effects of PDL therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368860431\">",
"    <span class=\"h2\">",
"     Other lasers and IPL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who fail to improve with PDL, other laser therapies can be tried [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/8\">",
"     8",
"    </a>",
"    ]. In a prospective study of 30 patients with PWS resistant to PDL, lesion color improved at least 25 percent in 16 patients (53 percent) after treatment with a modulated 532 nm frequency-doubled Nd:YAG laser [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/38\">",
"     38",
"    </a>",
"    ]. Scarring, hyperpigmentation, and prolonged time to healing occurred in six patients (20 percent).",
"   </p>",
"   <p>",
"    Near-infrared lasers, such as the 1064 Nd:YAG, alexandrite, and diode lasers have also been used for the treatment of PWS, and may be particularly useful for violaceous or nodular lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/8,39-41\">",
"     8,39-41",
"    </a>",
"    ]. However, the risk of scarring is significant at the relatively high fluences required to treat vascular lesions with near-infrared lasers. (See",
"    <a class=\"local\" href=\"#H113212036\">",
"     'Near-infrared lasers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The efficacy of PDL was compared with IPL in a randomized, side-by-side comparison trial of 20 patients who had not been previously treated with either therapy. A single treatment with a 595 nm PDL was superior to IPL for the induction of lesion clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/42\">",
"     42",
"    </a>",
"    ]. However, a pilot study found that IPL may have benefit for some patients with PWS; out of 15 patients with PDL-resistant PWS, six (40 percent) achieved more than 75 percent clearance with IPL [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/43\">",
"     43",
"    </a>",
"    ]. In general, our preference is to use lasers rather than IPL for the treatment of PWS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12910455\">",
"    <span class=\"h2\">",
"     Emerging therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined modality lasers (eg, 595 and 1064 nm) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/8\">",
"     8",
"    </a>",
"    ], photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/44-46\">",
"     44-46",
"    </a>",
"    ], and the combination of PDL plus topical agents with antiangiogenic properties, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    , may have benefit for the treatment of PWS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Further studies are necessary to explore the efficacy and safety of these therapies in PWS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12910462\">",
"    <span class=\"h1\">",
"     INFANTILE HEMANGIOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile hemangiomas are the most common benign vascular tumors in children. Lesions are present at birth or become evident during the first several weeks of life. Infantile hemangiomas may be superficial (capillary), deep (cavernous), or may have a mixture of superficial and deep components (",
"    <a class=\"graphic graphic_picture graphicRef60004 graphicRef50388 graphicRef60003 graphicRef72298 graphicRef74768 graphicRef68162 graphicRef50631 \" href=\"UTD.htm?37/44/38602\">",
"     picture 4A-G",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/50\">",
"     50",
"    </a>",
"    ]. Superficial hemangiomas typically present as bright red papules, plaques or nodules. Deep lesions appear as flesh-colored or bluish subcutaneous nodules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5495?source=see_link\">",
"     \"Evaluation and diagnosis of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=see_link\">",
"     \"Management of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history of hemangiomas (rapid proliferation over the course of months followed by involution over the course of a few to several years) raises questions about the need for therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/51\">",
"     51",
"    </a>",
"    ]. Most hemangiomas are managed conservatively, with close observation for the development of complications. Topical therapies, systemic medications, and occasionally surgical intervention are used for the treatment of hemangiomas that require treatment secondary to the impairment of vital functions (eg, vision or feeding) or ulceration. Patients with proliferating lesions in sites that are likely to leave significant deformities following involution are also often considered for therapy. Laser therapy has emerged as an additional therapeutic option; however, study results vary on the efficacy of this treatment. Based upon the available data, beneficial effects of laser therapy are most likely to occur in patients with superficial or ulcerated lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12728565\">",
"    <span class=\"h2\">",
"     Efficacy of PDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsed dye lasers (PDLs) are the most common lasers used for the treatment of infantile hemangiomas. However, study results vary on their efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/52-57\">",
"     52-57",
"    </a>",
"    ]. Interpretation of the literature is further complicated by the natural course towards lesional involution, variations in laser settings among studies, and the evolution of laser technology over time [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/52,54\">",
"     52,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although beneficial effects of PDL therapy have been reported in multiple uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/52,53,56,57\">",
"     52,53,56,57",
"    </a>",
"    ], the contradictory results of a randomized trial raised controversy over the use of PDL for this indication [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/55\">",
"     55",
"    </a>",
"    ]. The trial found that the number of children with complete hemangioma clearance at one year was significantly greater in the group treated with a 585 nm PDL without epidermal cooling technology (fluence 6 to 7.5",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    spot size 3 to 5 mm, pulse duration 0.45 ms) than in the observation group (30 versus 5 percent, respectively). However, no difference between the groups was detected when the sum of patients with either complete clearance or minimal residual signs of hemangioma at one year were analyzed. In addition, lesion redness was the only objective measure that was found to significantly improve with treatment, and adverse effects of skin atrophy and hypopigmentation occurred at a higher rate in the treated group. Given the lack of use of modern epidermal cooling techniques and the small spot sizes used, the applicability of the results to current practice have been questioned.",
"   </p>",
"   <p>",
"    Integrated cooling techniques allow the safe use of higher and potentially more effective fluences. This fact, plus the theoretical potential for deeper skin penetration with the 595 nm PDL compared with the 585 nm PDL, led to the use of 595 nm PDLs with integrated cooling technology for the treatment of infantile hemangiomas. The following studies support the use of these lasers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 121 infants with hemangiomas, the efficacy of a 595 nm PDL with cryogen spray cooling technology (fluence 9 to 15",
"      <span class=\"nowrap\">",
"       J/cm",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      spot size 7 mm, pulse duration 10 to 20 ms) was compared to a 585 nm PDL without cooling technology (fluence 5.5 to 7",
"      <span class=\"nowrap\">",
"       J/cm",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      spot size 7 mm, pulse duration 0.45 ms) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/58\">",
"       58",
"      </a>",
"      ]. Although similar numbers of patients achieved complete or near complete lesion clearance at one year (approximately 60 percent), patients treated with the 595 nm laser were found to have shorter periods of maximum lesion proliferation (106 versus 177 days) and a lower risk for laser-induced hypopigmentation, hyperpigmentation, and textural skin changes.",
"     </li>",
"     <li>",
"      In a retrospective study of 90 patients with 105 superficial or superficial and deep hemangiomas, treatment with a 595 nm PDL with a dynamic spray cooling device (fluence 6.2 to 14",
"      <span class=\"nowrap\">",
"       J/cm2,",
"      </span>",
"      spot size 7 or 10 mm, pulse duration 0.45 or 1.5 ms) appeared to be beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/52\">",
"       52",
"      </a>",
"      ]. Among the study patients, 85 percent exhibited near complete or complete clearance of lesion color and 64 percent exhibited near complete or complete resolution of lesion thickness (mean number of treatments = 6.7&plusmn;4.5).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to laser types and settings, patient-specific and lesion-specific characteristics, such as lesion stage, patient age, and lesion depth may influence the efficacy of treatment. Ulceration, a complication that occurs in some infantile hemangiomas, can respond to PDL therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200669643\">",
"    <span class=\"h3\">",
"     Lesion stage and patient age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal timing of PDL therapy in infantile hemangiomas remains uncertain. Beneficial effects of early PDL therapy are supported by the results of a prospective study of 165 children treated with a 585 nm PDL. In this study, initial hemangiomas were more likely to lighten in color than actively proliferating lesions and required fewer treatments to achieve improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/56\">",
"     56",
"    </a>",
"    ]. Some authors have suggested that early treatment of hemangiomas (prior to the proliferative stage) also may inhibit the proliferation of deeper components [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/29\">",
"     29",
"    </a>",
"    ]. However, studies conflict on the validity of this theory [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/55-57,59\">",
"     55-57,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=see_link\">",
"     \"Management of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although patient age often loosely correlates with lesion stage, age may not be an independent determining factor for the efficacy of treatment. In a prospective study of 548 children (age 3 to 36 months) with 692 proliferating hemangiomas who were treated with a 585 nm PDL, mean scores for response to treatment did not differ according to patient age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superficial involuting lesions may respond best to treatment, indicating that when desired, PDL may be useful for accelerating clinical resolution of actively involuting lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H461968457\">",
"     'Involuting and resolved lesions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200669562\">",
"    <span class=\"h3\">",
"     Superficial versus deep",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial hemangiomas may be more likely to respond completely to laser therapy than deeper lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/52,57\">",
"     52,57",
"    </a>",
"    ], an observation that is consistent with the known limits of penetration PDL light into the skin. In a prospective study of 165 children with 225 hemangiomas, complete clearance of lesions followed 585 nm PDL therapy in 52 out of 153 (34 percent) superficial hemangiomas (mean number of treatments for complete response = 1.6&plusmn;1.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/56\">",
"     56",
"    </a>",
"    ]. In contrast, none of 54 mixed cutaneous-subcutaneous hemangiomas exhibited complete clearance.",
"   </p>",
"   <p>",
"    Another prospective study of 548 children with hemangiomas also found higher rates of complete responses to 585 nm PDL therapy in superficial lesions; complete remissions occurred most frequently in small superficial hemangiomas (43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/57\">",
"     57",
"    </a>",
"    ]. Larger superficial lesions, cutaneous nodular, and mixed (cutaneous and subcutaneous) lesions resolved in 19, 15, and 7 percent of cases, respectively.",
"   </p>",
"   <p>",
"    Superficial lesions may also respond more favorably to the slightly more deeply penetrating 595 long-pulse PDL. Although a retrospective study of 90 patients with 105 superficial or deep hemangiomas treated with the laser every two to eight weeks found that &ge;75 percent improvements in color occurred in similar proportions of patients with superficial or mixed lesions (approximately 80 percent), greater reductions in lesion thickness were observed in superficial lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/52\">",
"     52",
"    </a>",
"    ]. Lesion thickness was reduced by at least 75 percent in 78 and 40 percent of lesions, respectively.",
"   </p>",
"   <p>",
"    As noted above, there is insufficient evidence to conclude that early treatment of hemangiomas influences the risk for the development of deep components. (See",
"    <a class=\"local\" href=\"#H200669643\">",
"     'Lesion stage and patient age'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175204223\">",
"    <span class=\"h3\">",
"     Ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of PDL for the treatment of ulceration in hemangiomas is supported by uncontrolled studies (",
"    <a class=\"graphic graphic_picture graphicRef68162 graphicRef74768 \" href=\"UTD.htm?1/59/1972\">",
"     picture 4E-F",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. As little as one treatment may be required to induce healing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In one study of 78 children with ulcerated hemangiomas, 71 (91 percent) responded to therapy with 585 nm PDL [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/63\">",
"     63",
"    </a>",
"    ]. An earlier retrospective study found less dramatic results; 11 out of 22 treated children exhibited definite improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/60\">",
"     60",
"    </a>",
"    ]. Pain reduction is another potential benefit of PDL treatment. In a series of nine infants with ulcerated hemangiomas, pain appeared to improve in all patients after one treatment with a 585 nm PDL [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, PDL therapy occasionally has also been associated with the development of ulceration in hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12728580\">",
"     'Precautions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12728573\">",
"    <span class=\"h2\">",
"     Clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commonly used parameters for the PDL in the treatment of infantile hemangiomas are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wavelength: 585 to 595 nm",
"     </li>",
"     <li>",
"      Fluence: 5 to 7.5",
"      <span class=\"nowrap\">",
"       J/cm",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (settings outside of this range are appropriate in some clinical settings)",
"     </li>",
"     <li>",
"      Pulse duration: 0.45 to 6 ms",
"     </li>",
"     <li>",
"      Spot size: 5 to 10 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We typically use a 595 nm PDL and select laser settings based upon multiple factors, including lesion stage (proliferating versus involuting), lesion location, and patient skin type. Low fluences (around 5",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    should be used for proliferating lesions to minimize risk of ulceration. The initial fluence setting should also be reduced for patients with dark skin and lesions in areas with thin skin (eg, eyelid).",
"   </p>",
"   <p>",
"    The often undulating surface of hemangiomas requires the clinician to play close attention to the correct positioning of the laser in relation to the skin (",
"    <a class=\"graphic graphic_picture graphicRef80239 \" href=\"UTD.htm?25/5/25680\">",
"     picture 2",
"    </a>",
"    ). Integrated skin cooling mechanisms are required and should be utilized to minimize the risk of epidermal damage during treatment.",
"   </p>",
"   <p>",
"    Treatments can be performed at two to four week intervals in rapidly proliferating or ulcerated lesions. Stable or involuting lesions may be treated less frequently every four to six weeks. Treatment is often performed without anesthesia; however, in occasional cases local or general anesthesia may be necessary for safe and effective treatment. (See",
"    <a class=\"local\" href=\"#H10061407\">",
"     'Anesthesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12728580\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary local swelling is a common adverse effect [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/29\">",
"     29",
"    </a>",
"    ]. Application of ice packs and elevation of the affected area may reduce symptoms. Hyperpigmentation or hypopigmentation is another potential consequence of PDL treatment. Severe pain, scarring, and life threatening hemorrhage have also been reported in patients treated with PDL for hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although PDLs are used for the treatment of ulceration in hemangiomas, treatment occasionally induces ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/64\">",
"     64",
"    </a>",
"    ]. The use of large spot sizes with low fluences and epidermal cooling mechanisms may help to minimize the risk of ulceration. Patients with diffuse segmental hemangiomas may be at increased risk for ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H383620142\">",
"    <span class=\"h2\">",
"     Other lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequency-doubled Nd:YAG (KTP) lasers have been used for the treatment of hemangiomas. However, a retrospective study in which 50 infants with 62 superficial hemangiomas were treated with a 585 nm PDL or a frequency doubled Nd:YAG (532 nm) found that treatment with the PDL was more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/66\">",
"     66",
"    </a>",
"    ]. Successful treatment of deep hemangiomas with intralesional KTP bare fibers has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there is little evidence for the efficacy of 1064 Nd:YAG lasers for infantile hemangiomas, some authors have suggested the cautious use of this laser for thicker hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/29\">",
"     29",
"    </a>",
"    ]. In one uncontrolled study of a sequential laser system that delivered 595 nm PDL and 1064 nm Nd:YAG light, excellent improvement occurred in 18 out of 25 hemangiomas involving the skin and mucous membranes of the head and neck (72 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/69\">",
"     69",
"    </a>",
"    ]. However, the relatively high risk of scarring associated with the 1064 Nd:YAG must be considered seriously prior to attempting treatment with this laser [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461968457\">",
"    <span class=\"h2\">",
"     Involuting and resolved lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangiomas in the involutional phase may benefit from treatment with PDL to hasten resolution of residual redness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fractionated lasers may be effective for improving fibrofatty residua that remain after involution of hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Fractional laser therapy appeared to be beneficial in a series of five children with involuted hemangioma residua who were treated with an ablative fractional CO2 laser [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/71\">",
"     71",
"    </a>",
"    ]. In addition, in an 18-year-old woman with residual fibrofatty tissue and redundant skin at the site of a previous facial hemangioma, treatment with a nonablative 1440 nm fractionated laser led to marked clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10061370\">",
"    <span class=\"h1\">",
"     TELANGIECTASIAS AND THE RED FACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectasias are common lesions that present as 0.1 to 1 mm diameter vascular dilatations that are visible on the skin (",
"    <a class=\"graphic graphic_picture graphicRef71614 \" href=\"UTD.htm?13/22/13667\">",
"     picture 5",
"    </a>",
"    ). Telangiectasias occur spontaneously or arise in the setting of other conditions, such as cutaneous photodamage, rosacea, connective tissue or liver disease, radiation, hereditary hemorrhagic telangiectasia, and long term topical corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/72\">",
"     72",
"    </a>",
"    ]. Patients with numerous telangiectasias on the face frequently present with a complaint of facial redness.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Telangiectasias and secondary facial redness do not require treatment, but lesions that are cosmetically distressing for patients can be removed with electrocautery or lasers. Lasers provide quick and effective therapy, particularly for multiple telangiectasias, large areas with telangiectasias, or lesions that have failed to resolve after electrocautery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461968721\">",
"    <span class=\"h2\">",
"     Clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of light sources are effective for the treatment of telangiectasias. PDLs are among the most commonly used; however, frequency-doubled Nd:YAG lasers and IPL are also effective. Lasers with longer wavelengths, such as the alexandrite, diode, and Nd:YAG are useful for targeting larger vessels that are located deeper in the skin. Laser spot sizes, and in some cases, the spot shape (round versus elliptical), can be adjusted to conform to the size or shape of the target vessel.",
"   </p>",
"   <p>",
"    PDL therapy can result in temporary purpura, which are viewed as unfavorable by many cosmetic patients (",
"    <a class=\"graphic graphic_picture graphicRef59618 \" href=\"UTD.htm?9/60/10176\">",
"     picture 3",
"    </a>",
"    ). Purpura can be minimized or eliminated by use of long pulse durations (&ge;6 ms) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/73\">",
"     73",
"    </a>",
"    ]; however, treatment with subpurpuric laser settings may be less efficacious, contributing to the need for additional treatment sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of purpura-inducing versus subpurpuric PDL settings was investigated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a split-face comparison study of nine patients with facial telangiectasias and erythema treated with a 595 nm long-pulse (6 ms) PDL, purpuric fluences were more effective at reducing vessel diameter and arborization of telangiectasias than multiple passes with subpurpuric laser settings [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/5\">",
"       5",
"      </a>",
"      ]. Subpurpuric fluences were more effective for the reduction of background erythema.",
"     </li>",
"     <li>",
"      In a split-face, nonblinded randomized trial in which patients were treated with a 595 nm PDL (10 ms pulse duration) at either purpuric or subpurpuric fluences, purpura-inducing treatments were more effective. The greatest benefit of treatment was observed in thick, dense telangiectasias [",
"      <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple passes or judicious pulse stacking can be used to improve treatment response when longer pulse durations are utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/36,74\">",
"     36,74",
"    </a>",
"    ]. Pulse stacking involves the immediate delivery of repeated pulses (usually two to three) to the same treatment area in an attempt to increase cumulative heating of the target vessels, while allowing sufficient time for epidermal cooling between pulses. Multiple passes and pulse stacking techniques should only be used by experienced clinicians. Cutaneous damage may occur if incorrect settings are used or if the skin response to treatment is not properly monitored. &nbsp;",
"   </p>",
"   <p>",
"    Millisecond pulsed 532 nm frequency-doubled Nd:YAG lasers and IPL can also be used to treat facial telangiectasias with minimal to no purpura [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461968728\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in other settings, the risks of laser therapy for telangiectasias include pigmentary alteration, blistering, ulceration, and scarring. Risks of ulceration and scarring are higher with long wavelength lasers, such as the 1064 nm Nd:YAG and 755 nm alexandrite lasers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10061377\">",
"    <span class=\"h1\">",
"     ROSACEA ASSOCIATED ERYTHEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rosacea is a multi-faceted disease which can present with a variety of cutaneous morphologies including telangiectasias, erythema, inflammatory acneiform lesions, and rhinophyma.",
"   </p>",
"   <p>",
"    Rosacea associated telangiectases are managed similarly to other telangiectases. Laser and light sources also are commonly used for facial erythema secondary to rosacea, and based upon our clinical experiences, treatment also can provide relief from accompanying symptoms of burning and stinging. (See",
"    <a class=\"local\" href=\"#H10061370\">",
"     'Telangiectasias and the red face'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Multiple light based treatments are generally required to achieve the desired clinical response. Intermittent therapy is often necessary to maintain improvement after the completion of a successful treatment course. Although some patients require retreatment every three months, others maintain disease control with treatments separated by several years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10061384\">",
"    <span class=\"h1\">",
"     OTHER CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10061393\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protective eyewear is essential for all individuals present in the treatment room. Clinical personnel must wear laser safety goggles that specifically protect against the wavelength of the laser used.",
"   </p>",
"   <p>",
"    Patient protective eyewear depends on the location to be treated. If nonfacial areas are to be treated, patients may wear laser safety goggles similar to those of the clinical staff. For treatment of the face outside of the periorbital area, protective pads specific for laser procedures or metal goggles padded with a thin layer of gauze can be used. Corneal shields inserted with the aid of ocular anesthetic drops and lubricant are required when the eyelid or immediate periorbital area is treated. Appropriate sizing and placement of the patient&rsquo;s eyewear should always be confirmed prior to starting a procedure.",
"   </p>",
"   <p>",
"    Eye injury has been reported when long pulsed longer wavelength (755 and 1064 nm) lasers were used within the bony orbit, even with appropriate eye protection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/76\">",
"     76",
"    </a>",
"    ]. Use of these devices in the periorbital area should be avoided or approached with extreme caution.",
"   </p>",
"   <p>",
"    Lasers have been reported to cause flash fires [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/77\">",
"     77",
"    </a>",
"    ]. To avoid this, alcohol used to clean instruments or skin must be completely dry before starting the procedure. Fire extinguishers should be immediately available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10061407\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anesthesia generally is not required for small lesions. Topical anesthetics can be used, although some preparations (eg, eutectic mixture of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    , EMLA&reg;) may blanch the vessels. This may remove the target, minimizing treatment response. Local anesthetic injections or regional nerve blocks can also be utilized; however, epinephrine (a vasoconstrictor) should be avoided to prevent vessel constriction and target removal.",
"    <strong>",
"     &nbsp;",
"    </strong>",
"   </p>",
"   <p>",
"    General anesthesia may be helpful to ensure safe and complete treatment of large lesions (PWS or hemangiomas) in infants, children, and some adults. The multiple treatments required and the use of protective eyewear, especially corneal shields, can be difficult for children. General anesthesia is routinely used for large lesions in children over the age of six months at the author&rsquo;s academic center.",
"   </p>",
"   <p>",
"    General anesthesia performed by experienced anesthesiologists in otherwise healthy children has been reported to be quite safe. One study reported no serious adverse events in a multicenter report of 881 dermatologic procedures performed on children aged 2 months to 18 years with general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/47/17146/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461968785\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lasers and intense pulsed light (IPL) are treatment options for a variety of vascular lesions, including telangiectasias, port wine stains (PWS), and infantile hemangiomas. (See",
"      <a class=\"local\" href=\"#H10061257\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacy of lasers and IPL for vascular lesions stems from the absorption of light by oxyhemoglobin in lesional vessels. Yellow and green light, and to a lesser extent, near-infrared light, are preferentially absorbed by oxyhemoglobin. Light sources that emit light in these ranges generally are used for the treatment of vascular lesions. (See",
"      <a class=\"local\" href=\"#H12728454\">",
"       'Principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulsed dye lasers (PDLs) are the lasers used most commonly for the treatment of vascular lesions. For patients with PWS who desire treatment, we recommend treatment with PDL over other therapies as first-line treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We typically utilize a 595 nm PDL with pulse duration of 0.45 ms or greater and an integrated mechanism to cool the epidermis. Fluences that induce purpura should be used, and multiple treatments are typically required to achieve significant improvement.",
"     </li>",
"     <li>",
"      Millisecond pulsed near-infrared lasers such as the 755 nm alexandrite or 1064 Nd:YAG laser may be useful for the treatment of thick or nodular PWS. However, the risk of scarring with long wavelength lasers exceeds risk with PDL, and the use of these lasers for PWS should be restricted to experienced clinicians. Other treatment options for PWS include the 532 nm frequency-doubled Nd:YAG laser, diode laser, and intense pulsed light (IPL).",
"     </li>",
"     <li>",
"      PWS in young children and lesions in certain locations may be more likely respond to therapy. Recurrence of PWS after treatment may occur. (See",
"      <a class=\"local\" href=\"#H2421284\">",
"       'Efficacy of PDL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laser treatment may be beneficial for select infantile hemangiomas. Small superficial, ulcerated, or involuting lesions exhibit the best responses to therapy. Evidence conflicts on whether early treatment of superficial hemangiomas inhibits future growth. (See",
"      <a class=\"local\" href=\"#H12910462\">",
"       'Infantile hemangiomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For ulcerated hemangiomas that fail to heal with local wound care, treatment with PDL is an option. In some cases, a single treatment is sufficient to induce healing of an ulcer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of infantile hemangiomas\", section on 'Ulceration'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H175204223\">",
"       'Ulceration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Telangiectasias are common, benign vascular lesions that are amenable to laser therapy. PDL and other vascular lasers can be effective for these lesions. (See",
"      <a class=\"local\" href=\"#H10061370\">",
"       'Telangiectasias and the red face'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/1\">",
"      Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/2\">",
"      Kelly KM, Choi B, McFarlane S, et al. Description and analysis of treatments for port-wine stain birthmarks. Arch Facial Plast Surg 2005; 7:287.",
"     </a>",
"    </li>",
"    <li>",
"     Mulliken JB, Young AR. Vascular Birthmarks&mdash;Hemangiomas and Malformations, WB Saunders Co, Philadelphia, PA 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/4\">",
"      van Gemert MJ, Welch AJ, Amin AP. Is there an optimal laser treatment for port wine stains? Lasers Surg Med 1986; 6:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/5\">",
"      Iyer S, Fitzpatrick RE. Long-pulsed dye laser treatment for facial telangiectasias and erythema: evaluation of a single purpuric pass versus multiple subpurpuric passes. Dermatol Surg 2005; 31:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/6\">",
"      Alam M, Dover JS, Arndt KA. Treatment of facial telangiectasia with variable-pulse high-fluence pulsed-dye laser: comparison of efficacy with fluences immediately above and below the purpura threshold. Dermatol Surg 2003; 29:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/7\">",
"      Civas E, Koc E, Aksoy B, Aksoy HM. Clinical experience in the treatment of different vascular lesions using a neodymium-doped yttrium aluminum garnet laser. Dermatol Surg 2009; 35:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/8\">",
"      Jasim ZF, Handley JM. Treatment of pulsed dye laser-resistant port wine stain birthmarks. J Am Acad Dermatol 2007; 57:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/9\">",
"      Ahcan U, Zorman P, Recek D, et al. Port wine stain treatment with a dual-wavelength Nd:Yag laser and cryogen spray cooling: a pilot study. Lasers Surg Med 2004; 34:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/10\">",
"      Hansen K, Kreiter CD, Rosenbaum M, et al. Long-term psychological impact and perceived efficacy of pulsed-dye laser therapy for patients with port-wine stains. Dermatol Surg 2003; 29:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/11\">",
"      McClean K, Hanke CW. The medical necessity for treatment of port-wine stains. Dermatol Surg 1997; 23:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/12\">",
"      Reyes BA, Geronemus R. Treatment of port-wine stains during childhood with the flashlamp-pumped pulsed dye laser. J Am Acad Dermatol 1990; 23:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/13\">",
"      Orten SS, Waner M, Flock S, et al. Port-wine stains. An assessment of 5 years of treatment. Arch Otolaryngol Head Neck Surg 1996; 122:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/14\">",
"      Fiskerstrand EJ, Svaasand LO, Kopstad G, et al. Laser treatment of port wine stains: therapeutic outcome in relation to morphological parameters. Br J Dermatol 1996; 134:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/15\">",
"      Alster TS, Wilson F. Treatment of port-wine stains with the flashlamp-pumped pulsed dye laser: extended clinical experience in children and adults. Ann Plast Surg 1994; 32:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/16\">",
"      Tan OT, Sherwood K, Gilchrest BA. Treatment of children with port-wine stains using the flashlamp-pulsed tunable dye laser. N Engl J Med 1989; 320:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/17\">",
"      Morelli JG, Weston WL, Huff JC, Yohn JJ. Initial lesion size as a predictive factor in determining the response of port-wine stains in children treated with the pulsed dye laser. Arch Pediatr Adolesc Med 1995; 149:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/18\">",
"      Nguyen CM, Yohn JJ, Huff C, et al. Facial port wine stains in childhood: prediction of the rate of improvement as a function of the age of the patient, size and location of the port wine stain and the number of treatments with the pulsed dye (585 nm) laser. Br J Dermatol 1998; 138:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/19\">",
"      Onizuka K, Tsuneda K, Shibata Y, et al. Efficacy of flashlamp-pumped pulsed dye laser therapy for port wine stains: clinical assessment and histopathological characteristics. Br J Plast Surg 1995; 48:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/20\">",
"      Renfro L, Geronemus RG. Anatomical differences of port-wine stains in response to treatment with the pulsed dye laser. Arch Dermatol 1993; 129:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/21\">",
"      Garden JM, Polla LL, Tan OT. The treatment of port-wine stains by the pulsed dye laser. Analysis of pulse duration and long-term therapy. Arch Dermatol 1988; 124:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/22\">",
"      van der Horst CM, Koster PH, de Borgie CA, et al. Effect of the timing of treatment of port-wine stains with the flash-lamp-pumped pulsed-dye laser. N Engl J Med 1998; 338:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/23\">",
"      Chapas AM, Eickhorst K, Geronemus RG. Efficacy of early treatment of facial port wine stains in newborns: a review of 49 cases. Lasers Surg Med 2007; 39:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/24\">",
"      Ashinoff R, Geronemus RG. Flashlamp-pumped pulsed dye laser for port-wine stains in infancy: earlier versus later treatment. J Am Acad Dermatol 1991; 24:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/25\">",
"      Minkis K, Geronemus RG, Hale EK. Port wine stain progression: a potential consequence of delayed and inadequate treatment? Lasers Surg Med 2009; 41:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/26\">",
"      Geronemus RG, Ashinoff R. The medical necessity of evaluation and treatment of port-wine stains. J Dermatol Surg Oncol 1991; 17:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/27\">",
"      Ho WS, Chan HH, Ying SY, Chan PC. Laser treatment of congenital facial port-wine stains: long-term efficacy and complication in Chinese patients. Lasers Surg Med 2002; 30:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/28\">",
"      Huikeshoven M, Koster PH, de Borgie CA, et al. Redarkening of port-wine stains 10 years after pulsed-dye-laser treatment. N Engl J Med 2007; 356:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/29\">",
"      Stier MF, Glick SA, Hirsch RJ. Laser treatment of pediatric vascular lesions: Port wine stains and hemangiomas. J Am Acad Dermatol 2008; 58:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/30\">",
"      Bernstein EF, Brown DB. Efficacy of the 1.5 millisecond pulse-duration, 585 nm, pulsed-dye laser for treating port-wine stains. Lasers Surg Med 2005; 36:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/31\">",
"      Greve B, Raulin C. Prospective study of port wine stain treatment with dye laser: comparison of two wavelengths (585 nm vs. 595 nm) and two pulse durations (0.5 milliseconds vs. 20 milliseconds). Lasers Surg Med 2004; 34:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/32\">",
"      Yung A, Sheehan-Dare R. A comparative study of a 595-nm with a 585-nm pulsed dye laser in refractory port wine stains. Br J Dermatol 2005; 153:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/33\">",
"      Frohm Nilsson M, Passian S, Wiegleb Edstrom D. Comparison of two dye lasers in the treatment of port-wine stains. Clin Exp Dermatol 2010; 35:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/34\">",
"      Bernstein EF. Treatment of a resistant port-wine stain with the 1.5-msec pulse duration, tunable, pulsed dye laser. Dermatol Surg 2000; 26:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/35\">",
"      Laube S, Taibjee S, Lanigan SW. Treatment of resistant port wine stains with the V Beam pulsed dye laser. Lasers Surg Med 2003; 33:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/36\">",
"      Tanghetti E, Sherr EA, Sierra R, Mirkov M. The effects of pulse dye laser double-pass treatment intervals on depth of vessel coagulation. Lasers Surg Med 2006; 38:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/37\">",
"      Cantatore JL, Kriegel DA. Laser surgery: an approach to the pediatric patient. J Am Acad Dermatol 2004; 50:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/38\">",
"      Chowdhury MM, Harris S, Lanigan SW. Potassium titanyl phosphate laser treatment of resistant port-wine stains. Br J Dermatol 2001; 144:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/39\">",
"      Izikson L, Anderson RR. Treatment endpoints for resistant port wine stains with a 755 nm laser. J Cosmet Laser Ther 2009; 11:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/40\">",
"      Yang MU, Yaroslavsky AN, Farinelli WA, et al. Long-pulsed neodymium:yttrium-aluminum-garnet laser treatment for port-wine stains. J Am Acad Dermatol 2005; 52:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/41\">",
"      Groot D, Rao J, Johnston P, Nakatsui T. Algorithm for using a long-pulsed Nd:YAG laser in the treatment of deep cutaneous vascular lesions. Dermatol Surg 2003; 29:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/42\">",
"      Faurschou A, Togsverd-Bo K, Zachariae C, Haedersdal M. Pulsed dye laser vs. intense pulsed light for port-wine stains: a randomized side-by-side trial with blinded response evaluation. Br J Dermatol 2009; 160:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/43\">",
"      Bjerring P, Christiansen K, Troilius A. Intense pulsed light source for the treatment of dye laser resistant port-wine stains. J Cosmet Laser Ther 2003; 5:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/44\">",
"      Yuan KH, Li Q, Yu WL, et al. Comparison of photodynamic therapy and pulsed dye laser in patients with port wine stain birthmarks: a retrospective analysis. Photodiagnosis Photodyn Ther 2008; 5:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/45\">",
"      Tournas JA, Lai J, Truitt A, et al. Combined benzoporphyrin derivative monoacid ring photodynamic therapy and pulsed dye laser for port wine stain birthmarks. Photodiagnosis Photodyn Ther 2009; 6:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/46\">",
"      Yuan KH, Li Q, Yu WL, Huang Z. Photodynamic therapy in treatment of port wine stain birthmarks--recent progress. Photodiagnosis Photodyn Ther 2009; 6:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/47\">",
"      Chang CJ, Hsiao YC, Mihm MC Jr, Nelson JS. Pilot study examining the combined use of pulsed dye laser and topical Imiquimod versus laser alone for treatment of port wine stain birthmarks. Lasers Surg Med 2008; 40:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/48\">",
"      Jia W, Sun V, Tran N, et al. Long-term blood vessel removal with combined laser and topical rapamycin antiangiogenic therapy: implications for effective port wine stain treatment. Lasers Surg Med 2010; 42:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/49\">",
"      Tremaine AM, Armstrong J, Huang YC, et al. Enhanced port-wine stain lightening achieved with combined treatment of selective photothermolysis and imiquimod. J Am Acad Dermatol 2012; 66:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/50\">",
"      Requena L, Sangueza OP. Cutaneous vascular proliferation. Part II. Hyperplasias and benign neoplasms. J Am Acad Dermatol 1997; 37:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/51\">",
"      Smolinski KN, Yan AC. Hemangiomas of infancy: clinical and biological characteristics. Clin Pediatr (Phila) 2005; 44:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/52\">",
"      Rizzo C, Brightman L, Chapas AM, et al. Outcomes of childhood hemangiomas treated with the pulsed-dye laser with dynamic cooling: a retrospective chart analysis. Dermatol Surg 2009; 35:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/53\">",
"      Hunzeker CM, Geronemus RG. Treatment of superficial infantile hemangiomas of the eyelid using the 595-nm pulsed dye laser. Dermatol Surg 2010; 36:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/54\">",
"      Chang CJ, Kelly KM, Nelson JS. Cryogen spray cooling and pulsed dye laser treatment of cutaneous hemangiomas. Ann Plast Surg 2001; 46:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/55\">",
"      Batta K, Goodyear HM, Moss C, et al. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet 2002; 360:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/56\">",
"      Poetke M, Philipp C, Berlien HP. Flashlamp-pumped pulsed dye laser for hemangiomas in infancy: treatment of superficial vs mixed hemangiomas. Arch Dermatol 2000; 136:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/57\">",
"      Hohenleutner S, Badur-Ganter E, Landthaler M, Hohenleutner U. Long-term results in the treatment of childhood hemangioma with the flashlamp-pumped pulsed dye laser: an evaluation of 617 cases. Lasers Surg Med 2001; 28:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/58\">",
"      Kono T, Sakurai H, Groff WF, et al. Comparison study of a traditional pulsed dye laser versus a long-pulsed dye laser in the treatment of early childhood hemangiomas. Lasers Surg Med 2006; 38:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/59\">",
"      Ashinoff R, Geronemus RG. Failure of the flashlamp-pumped pulsed dye laser to prevent progression to deep hemangioma. Pediatr Dermatol 1993; 10:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/60\">",
"      Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001; 44:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/61\">",
"      Morelli JG, Tan OT, Weston WL. Treatment of ulcerated hemangiomas with the pulsed tunable dye laser. Am J Dis Child 1991; 145:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/62\">",
"      Wananukul S, Chatproedprai S. Ulcerated hemangiomas: clinical features and management. J Med Assoc Thai 2002; 85:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/63\">",
"      David LR, Malek MM, Argenta LC. Efficacy of pulse dye laser therapy for the treatment of ulcerated haemangiomas: a review of 78 patients. Br J Plast Surg 2003; 56:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/64\">",
"      Witman PM, Wagner AM, Scherer K, et al. Complications following pulsed dye laser treatment of superficial hemangiomas. Lasers Surg Med 2006; 38:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/65\">",
"      Maguiness SM, Frieden IJ. Current management of infantile hemangiomas. Semin Cutan Med Surg 2010; 29:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/66\">",
"      Raulin C, Greve B. Retrospective clinical comparison of hemangioma treatment by flashlamp-pumped (585 nm) and frequency-doubled Nd:YAG (532 nm) lasers. Lasers Surg Med 2001; 28:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/67\">",
"      Burstein FD, Williams JK, Schwentker AR, Nahai F. Intralesional laser therapy treatment for hemangiomas: technical evolution. J Craniofac Surg 2006; 17:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/68\">",
"      Achauer BM, Celikoz B, VanderKam VM. Intralesional bare fiber laser treatment of hemangioma of infancy. Plast Reconstr Surg 1998; 101:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/69\">",
"      Saafan AM, Salah MM. Using pulsed dual-wavelength 595 and 1064 nm is more effective in the management of hemangiomas. J Drugs Dermatol 2010; 9:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/70\">",
"      Blankenship CM, Alster TS. Fractional photothermolysis of residual hemangioma. Dermatol Surg 2008; 34:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/71\">",
"      Brightman LA, Brauer JA, Terushkin V, et al. Ablative fractional resurfacing for involuted hemangioma residuum. Arch Dermatol 2012; 148:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/72\">",
"      Hare McCoppin HH, Goldberg DJ. Laser treatment of facial telangiectases: an update. Dermatol Surg 2010; 36:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/73\">",
"      Jasim ZF, Woo WK, Handley JM. Long-pulsed (6-ms) pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold. Dermatol Surg 2004; 30:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/74\">",
"      Rohrer TE, Chatrath V, Iyengar V. Does pulse stacking improve the results of treatment with variable-pulse pulsed-dye lasers? Dermatol Surg 2004; 30:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/75\">",
"      Clementoni MT, Gilardino P, Muti GF, et al. Facial teleangectasias: our experience in treatment with IPL. Lasers Surg Med 2005; 37:9.",
"     </a>",
"    </li>",
"    <li>",
"     Biesman BJ.  Presentation at Controversies and Conversations in Laser and Cosmetic Surgery, Colorado Springs, Colorado August 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/77\">",
"      Waldorf HA, Kauvar NB, Geronemus RG, Leffel DJ. Remote fire with the pulsed dye laser: risk and prevention. J Am Acad Dermatol 1996; 34:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/47/17146/abstract/78\">",
"      Cunningham BB, Gigler V, Wang K, et al. General anesthesia for pediatric dermatologic procedures: risks and complications. Arch Dermatol 2005; 141:573.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13638 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17146=[""].join("\n");
var outline_f16_47_17146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H461968785\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10061257\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12728454\">",
"      PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12728466\">",
"      VASCULAR LASERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H113212014\">",
"      Yellow and green light lasers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3923207\">",
"      - Pulsed dye laser",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12728497\">",
"      - Frequency-doubled Nd:YAG (KTP) lasers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H113212036\">",
"      Near-infrared lasers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H113212064\">",
"      Dual wavelength lasers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3923257\">",
"      Intense pulsed light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10061356\">",
"      PORT WINE STAINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2421284\">",
"      Efficacy of PDL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175203890\">",
"      - Patient age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175203897\">",
"      - Lesion location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175203904\">",
"      - Lesion characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175204195\">",
"      - Dark skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175204202\">",
"      - Long term efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12728550\">",
"      Clinical use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368860500\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368860431\">",
"      Other lasers and IPL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12910455\">",
"      Emerging therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12910462\">",
"      INFANTILE HEMANGIOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12728565\">",
"      Efficacy of PDL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H200669643\">",
"      - Lesion stage and patient age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H200669562\">",
"      - Superficial versus deep",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175204223\">",
"      - Ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12728573\">",
"      Clinical use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12728580\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H383620142\">",
"      Other lasers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H461968457\">",
"      Involuting and resolved lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10061370\">",
"      TELANGIECTASIAS AND THE RED FACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H461968721\">",
"      Clinical use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H461968728\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10061377\">",
"      ROSACEA ASSOCIATED ERYTHEMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10061384\">",
"      OTHER CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10061393\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10061407\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461968785\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13638\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13638|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/61/2002\" title=\"picture 1A\">",
"      Bilateral port wine stains in SWS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/21/33105\" title=\"picture 1B\">",
"      Sturge-Weber syndrome - bilateral PWS infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/24/34177\" title=\"picture 1C\">",
"      Port wine stain - leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/5/25680\" title=\"picture 2\">",
"      Laser-skin position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/60/10176\" title=\"picture 3\">",
"      Laser induced purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/7/11390\" title=\"picture 4A\">",
"      Superficial hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/60/28623\" title=\"picture 4B\">",
"      Deep hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/32/512\" title=\"picture 4C\">",
"      Lip hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/3/17471\" title=\"picture 4D\">",
"      Lumbosacral hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/51/12095\" title=\"picture 4E\">",
"      Ulcerated hemangioma perineum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/52/24384\" title=\"picture 4F\">",
"      Ulcerated hemangioma axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/12/42181\" title=\"picture 4G\">",
"      Periocular hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/22/13667\" title=\"picture 5\">",
"      Telangiectasia nose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13638|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 1\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32151?source=related_link\">",
"      Basic principles of medical lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5495?source=related_link\">",
"      Evaluation and diagnosis of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25546?source=related_link\">",
"      Management of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=related_link\">",
"      Principles of laser and intense pulsed light for cutaneous lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=related_link\">",
"      Vascular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_47_17147="Differential diagnosis painless scrotal mass";
var content_f16_47_17147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of painless scrotal mass in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mass",
"       </td>",
"       <td class=\"subtitle1\">",
"        Palpation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transilluminates?",
"       </td>",
"       <td class=\"subtitle1\">",
"        Increases with Valsalva maneuver?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor",
"       </td>",
"       <td>",
"        Firm",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicocele",
"       </td>",
"       <td>",
"        \"Bag of worms\"",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noncommunicating hydrocele",
"       </td>",
"       <td>",
"        Fluid-filled",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spermatocele",
"       </td>",
"       <td>",
"        Small, soft, and localized cyst",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from From Kapphahn, C, Schlossberger, N. Diagnostic approach to scrotal masses. Adolescent Health Update 1992; 5:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17147=[""].join("\n");
var outline_f16_47_17147=null;
var title_f16_47_17148="Drugs that induce seizures";
var content_f16_47_17148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents reported to induce seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Analgesics",
"       </td>",
"       <td>",
"        Fentanyl, mefenamic acid, meperidine, pentazocine, propoxyphene, tramadol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Antibiotics",
"       </td>",
"       <td>",
"        Ampicillin, carbenicillin, cephalosporine, imipenem, isoniazid, lindane, metronidazole, nalidixic acid, oxacillin, penicillin, pyrimethamine, ticarcillin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Antidepressants",
"       </td>",
"       <td>",
"        Amitriptyline, bupropion, doxepin, maprotiline, mianserin, nomifensine, nortriptyline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Antineoplastic agents",
"       </td>",
"       <td>",
"        Busulfan, carmustine (BCNU), chlorambucil, cytosine arabinoside, methotrexate, vincristine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Antipsychotics",
"       </td>",
"       <td>",
"        Chlorpromazine, haloperidol, perphenazine, prochlorperazine, thioridazine, trifluoperazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Bronchial agents",
"       </td>",
"       <td>",
"        Aminophylline, theophylline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        General anesthetics",
"       </td>",
"       <td>",
"        Enflurane, ketamine, methohexital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Local anesthetics",
"       </td>",
"       <td>",
"        Bupivacaine, lidocaine, procaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Sympathomimetics",
"       </td>",
"       <td>",
"        Ephedrine, phenylpropanolamine, terbutaline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Others",
"       </td>",
"       <td>",
"        Alcohol, amphetamines, anticholinergics, antihistamines, aqueous iodinated contrast agents, atenolol, baclofen, cyclosporine, domperidone, ergonovine, flumazenil, folic acid, foscarnet, hyperbaric oxygen, insulin, lithium, methylphenidate, methylxanthines, ondansetron*, oxytocin, phencyclidine, tacrolimus (FK506)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Singh, NN, Rai, A, Selhorst, JB, Acharya, JN, Ondansetron and seizures. Epilepsia 2009; 50:2663.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenschenk S, Gilmore RL. Seizures associated with nonneurologic medical conditions. In: The Treatment of Epilepsy: Principles and Practice, 4th ed, Gupta A, Lachhwani DK (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17148=[""].join("\n");
var outline_f16_47_17148=null;
var title_f16_47_17149="Energy conservation methods";
var content_f16_47_17149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ways to conserve energy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Planning and organizing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alternate tasks that take lots of energy with those that take less.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plan activities daily as well as weekly to better alternate tasks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delegate as much as possible. It helps you get tasks done and it makes those who want to help feel useful.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eliminate steps or tasks that are not essential by combining chores or errands.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrange your household so that most activities can be done on one floor.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organize ahead of time so you don't have to rush.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pacing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Balance activities so you alternate resting and doing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stop to rest before you get tired even if it means stopping in the middle of a task.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Try to avoid spurts of activity; this can drain energy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pace activities on good days as well as bad days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop a routine to prevent overdoing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Positioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sit to do things whenever possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use",
"assistive devices: walkers, scooters, canes, handrails, crutches, grab",
"bars. Assistive devices and adaptive equipment can save energy by",
"allowing you to do things without having to bend or reach.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid heavy lifting (such as children, pots and pans, and laundry).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use carts or wagons to move things from room to room and place to place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wear a fanny pack, carpenter's belt, or jacket or sweater with pockets to carry things.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prioritizing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focus on things you enjoy doing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be realistic with yourself.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        When you're too tired to eat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        When just the thought of cooking or eating a meal makes you tired, try these hints to save energy:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Let others help prepare or bring food. Family or friends usually like to help!",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Shop at less busy times.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Meal preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assemble all ingredients before starting.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use mixes or pre-packaged foods.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use cookware you can serve from.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use small, lightweight appliances and labor saving devices.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buy utensils that fit comfortably in the hand.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Store frequently used items at chest level to minimize bending and reaching.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Line ovens and drip pans with foil for easier cleanup.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Let dishes air dry or use a dishwasher.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Childcare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plan activities or outings at a place that will allow you to sit or lie down.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Take advantage of daycare programs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teach children to make a game out of household chores.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plan work around your best times of the day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organize work centers so that equipment is within easy reach.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Create short cuts.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Take rest breaks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Work part time if possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Leisure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plan activities that allow you to sit or lie down.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plan social events at peak energy times.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17149=[""].join("\n");
var outline_f16_47_17149=null;
var title_f16_47_17150="In vitro activity against Candida species";
var content_f16_47_17150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    In vitro activity against Candida species",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Species",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Antifungal agent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Percent of isolates resistant to each antifungal agent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        ICU",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Non-ICU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        N",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent resistant",
"       </td>",
"       <td class=\"subtitle3\">",
"        N",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent resistant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        <em>",
"         C. albicans",
"        </em>",
"       </td>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        393",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        461",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        393",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        461",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        393",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        431",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        393",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        461",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        393",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        461",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        393",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        461",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        <em>",
"         C. glabrata",
"        </em>",
"       </td>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        4.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        <em>",
"         C. parapsilosis",
"        </em>",
"       </td>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        <em>",
"         C. tropicalis",
"        </em>",
"       </td>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        <em>",
"         C. krusei",
"        </em>",
"       </td>",
"       <td>",
"        Anidulafungin",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caspofungin",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micafungin",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posaconazole",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    ICU: intensive care unit.",
"    <div class=\"footnotes\">",
"     * Resistance is defined as a minimum inhibitory concentration (MIC)  &gt;0.5 mcg/mL for anidulafungin, caspofungin, micafungin against",
"     <em>",
"      C. albicans, C. tropicalis",
"     </em>",
"     , and",
"     <em>",
"      C. krusei",
"     </em>",
"     , and as a MIC  &gt;4 mcg/mL against",
"     <em>",
"      C. parapsilosis",
"     </em>",
"     . Resistance is defined as an MIC  &gt;0.5 mcg/mL for anidulafungin and caspofungin and as an MIC &gt;0.12 mcg/mL for micafungin against",
"     <em>",
"      C. glabrata",
"     </em>",
"     ; and as an MIC &gt;2 mcg/mL for posaconazole and voriconazole against all Candida species.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     N = Total number of isolates tested.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Pfaller MA, Messer SA, Moet GJ, et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J&nbsp;Antimicrob Agents 2011; 38:65. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17150=[""].join("\n");
var outline_f16_47_17150=null;
var title_f16_47_17151="Ulceration mandibular vestibule";
var content_f16_47_17151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mouth ulceration in a child with Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear ulceration deep in the mandibular vestibule (arrow) in a child with Crohn's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hardy S, Fleming P, Rowland M, et al. A prospective study of the oral manefestations of Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:886. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_47_17151=[""].join("\n");
var outline_f16_47_17151=null;
